NO147672B - ANALOGUE PROCEDURE FOR PREPARING N-ARYL-N- (1-L1-4-PIPERIDINYL) -ARYLACETAMIDES - Google Patents
ANALOGUE PROCEDURE FOR PREPARING N-ARYL-N- (1-L1-4-PIPERIDINYL) -ARYLACETAMIDES Download PDFInfo
- Publication number
- NO147672B NO147672B NO763054A NO763054A NO147672B NO 147672 B NO147672 B NO 147672B NO 763054 A NO763054 A NO 763054A NO 763054 A NO763054 A NO 763054A NO 147672 B NO147672 B NO 147672B
- Authority
- NO
- Norway
- Prior art keywords
- parts
- piperidinyl
- phenyl
- mixture
- filtered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 239000000203 mixture Substances 0.000 claims description 72
- 150000001875 compounds Chemical class 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 31
- 239000000047 product Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- -1 dihydroxyphenyl Chemical group 0.000 claims description 18
- 239000003054 catalyst Substances 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- PZXDYQVSAFZTBI-UHFFFAOYSA-N n-(4-chlorophenyl)-2-phenyl-n-piperidin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1N(C(=O)CC=1C=CC=CC=1)C1CCNCC1 PZXDYQVSAFZTBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000007858 starting material Substances 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 2
- ORAWRMFWMOWNSJ-UHFFFAOYSA-N 2-(3-chlorophenyl)-N-(1-cyclohexylpiperidin-4-yl)-N-phenylacetamide Chemical compound ClC=1C=C(C=CC1)CC(=O)N(C1=CC=CC=C1)C1CCN(CC1)C1CCCCC1 ORAWRMFWMOWNSJ-UHFFFAOYSA-N 0.000 claims 1
- PYPMKORNJLTHGP-UHFFFAOYSA-N 2-(3-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=CC(Cl)=C1 PYPMKORNJLTHGP-UHFFFAOYSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- XHOJAWVAWFHGHL-UHFFFAOYSA-N lorcainide Chemical compound C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 XHOJAWVAWFHGHL-UHFFFAOYSA-N 0.000 claims 1
- OKUKTFTVDGOSEF-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)-2-phenylacetamide Chemical compound C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 OKUKTFTVDGOSEF-UHFFFAOYSA-N 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 108
- 239000000243 solution Substances 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 60
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 238000002844 melting Methods 0.000 description 42
- 230000008018 melting Effects 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
- 238000010992 reflux Methods 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 27
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 24
- 238000003756 stirring Methods 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 17
- 229960001701 chloroform Drugs 0.000 description 17
- 239000000284 extract Substances 0.000 description 17
- 239000012458 free base Substances 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 10
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 7
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 150000004982 aromatic amines Chemical class 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000012258 stirred mixture Substances 0.000 description 5
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- DATNJFUARYITEM-UHFFFAOYSA-N ethyl 4-(2,6-dimethylanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=C(C)C=CC=C1C DATNJFUARYITEM-UHFFFAOYSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 150000002825 nitriles Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010015856 Extrasystoles Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 238000010934 O-alkylation reaction Methods 0.000 description 3
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- MOVXNHXUSMSOGD-UHFFFAOYSA-N ethyl 4-(4-chloroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=CC=C(Cl)C=C1 MOVXNHXUSMSOGD-UHFFFAOYSA-N 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 3
- WTOYUGZUPNQZHG-UHFFFAOYSA-N (4-anilino-1-benzylpiperidin-4-yl)methanol Chemical compound C1CC(CO)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 WTOYUGZUPNQZHG-UHFFFAOYSA-N 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- QBUUEBUUMUYSIY-UHFFFAOYSA-N 1-benzyl-4-(methoxymethyl)-n-phenylpiperidin-4-amine Chemical compound C1CC(COC)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 QBUUEBUUMUYSIY-UHFFFAOYSA-N 0.000 description 2
- BGGKEDDFKBVTDK-UHFFFAOYSA-N 2-(3-methylphenyl)acetyl chloride Chemical compound CC1=CC=CC(CC(Cl)=O)=C1 BGGKEDDFKBVTDK-UHFFFAOYSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- MWJKXKBVWIHKOB-UHFFFAOYSA-N 4-(methoxymethyl)-n-phenylpiperidin-4-amine Chemical compound C=1C=CC=CC=1NC1(COC)CCNCC1 MWJKXKBVWIHKOB-UHFFFAOYSA-N 0.000 description 2
- QNDVTIFLVWHAJR-UHFFFAOYSA-N 4-anilino-1-benzylpiperidine-4-carboxylic acid;dihydrochloride Chemical compound Cl.Cl.C1CC(C(=O)O)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 QNDVTIFLVWHAJR-UHFFFAOYSA-N 0.000 description 2
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 230000006181 N-acylation Effects 0.000 description 2
- 238000007126 N-alkylation reaction Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000004645 aluminates Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- QMZDDBFLGAVLCG-UHFFFAOYSA-N ethyl 4-(2,6-dichlorophenyl)iminopiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1=NC1=C(Cl)C=CC=C1Cl QMZDDBFLGAVLCG-UHFFFAOYSA-N 0.000 description 2
- GPASGQWFOBSQJW-UHFFFAOYSA-N ethyl 4-(2,6-dimethyl-n-(2-phenylacetyl)anilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1N(C=1C(=CC=CC=1C)C)C(=O)CC1=CC=CC=C1 GPASGQWFOBSQJW-UHFFFAOYSA-N 0.000 description 2
- VNDZDCXYCUNCJD-UHFFFAOYSA-N ethyl 4-(2-chloro-n-(2-phenylacetyl)anilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1N(C=1C(=CC=CC=1)Cl)C(=O)CC1=CC=CC=C1 VNDZDCXYCUNCJD-UHFFFAOYSA-N 0.000 description 2
- IEWGVRLUCGRTRP-UHFFFAOYSA-N ethyl 4-(4-chloro-n-(2-phenylacetyl)anilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 IEWGVRLUCGRTRP-UHFFFAOYSA-N 0.000 description 2
- YYUMXYYEDHMYQW-UHFFFAOYSA-N ethyl 4-(4-chlorophenyl)iminopiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1=NC1=CC=C(Cl)C=C1 YYUMXYYEDHMYQW-UHFFFAOYSA-N 0.000 description 2
- LUBGFMZTGFXIIN-UHFFFAOYSA-N ethyl 4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)CC1 LUBGFMZTGFXIIN-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- PGHNBPLEZJYPMH-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)pyridin-3-amine Chemical compound C=1C=CC=CC=1CN(CC1)CCC1NC1=CC=CN=C1 PGHNBPLEZJYPMH-UHFFFAOYSA-N 0.000 description 2
- JZMJTOMXVMWFES-UHFFFAOYSA-N n-(1-cyclopentylpiperidin-4-yl)pyrimidin-2-amine Chemical compound C1CCCC1N1CCC(NC=2N=CC=CN=2)CC1 JZMJTOMXVMWFES-UHFFFAOYSA-N 0.000 description 2
- CVTBGLRLBNLKPS-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-1-methylpiperidin-4-amine Chemical compound C1CN(C)CCC1NC1=C(C)C=CC=C1C CVTBGLRLBNLKPS-UHFFFAOYSA-N 0.000 description 2
- NYKYCCXAHBGMOF-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-phenyl-n-piperidin-4-ylacetamide Chemical compound CC1=CC=CC(C)=C1N(C(=O)CC=1C=CC=CC=1)C1CCNCC1 NYKYCCXAHBGMOF-UHFFFAOYSA-N 0.000 description 2
- BGOHVARCGIKWKF-UHFFFAOYSA-N n-(4-chlorophenyl)-2-phenyl-n-piperidin-4-ylacetamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N(C(=O)CC=1C=CC=CC=1)C1CCNCC1 BGOHVARCGIKWKF-UHFFFAOYSA-N 0.000 description 2
- BXHQWMYNPLCDME-UHFFFAOYSA-N n-phenyl-1-propan-2-ylpiperidin-4-amine Chemical compound C1CN(C(C)C)CCC1NC1=CC=CC=C1 BXHQWMYNPLCDME-UHFFFAOYSA-N 0.000 description 2
- HYVZYRXWWJQMTG-UHFFFAOYSA-N n-phenyl-1-propan-2-ylpiperidin-4-imine Chemical compound C1CN(C(C)C)CCC1=NC1=CC=CC=C1 HYVZYRXWWJQMTG-UHFFFAOYSA-N 0.000 description 2
- UUXXGTMOTIUHPW-UHFFFAOYSA-N n-piperidin-4-ylpyridin-3-amine Chemical compound C1CNCCC1NC1=CC=CN=C1 UUXXGTMOTIUHPW-UHFFFAOYSA-N 0.000 description 2
- HQPSCRCCYZGOIV-UHFFFAOYSA-N n-piperidin-4-ylpyrimidin-2-amine Chemical compound C1CNCCC1NC1=NC=CC=N1 HQPSCRCCYZGOIV-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- GJMLOLFRXRFRHB-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-(1-cyclopentylpiperidin-4-yl)-2-(3-methylphenyl)-n-pyridin-3-ylacetamide Chemical compound OC(=O)\C=C\C(O)=O.CC1=CC=CC(CC(=O)N(C2CCN(CC2)C2CCCC2)C=2C=NC=CC=2)=C1 GJMLOLFRXRFRHB-WLHGVMLRSA-N 0.000 description 1
- PRPRYWXCMOPROS-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-phenyl-n-(1-propan-2-ylpiperidin-4-yl)-2-thiophen-2-ylacetamide Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C(C)C)CCC1N(C=1C=CC=CC=1)C(=O)CC1=CC=CS1 PRPRYWXCMOPROS-WLHGVMLRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VBHVOXFCCJJTSK-UHFFFAOYSA-N 1-benzyl-n-pyridin-3-ylpiperidin-4-imine Chemical compound C=1C=CC=CC=1CN(CC1)CCC1=NC1=CC=CN=C1 VBHVOXFCCJJTSK-UHFFFAOYSA-N 0.000 description 1
- CCDBCHAQIXKJCG-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-one Chemical compound CC(C)N1CCC(=O)CC1 CCDBCHAQIXKJCG-UHFFFAOYSA-N 0.000 description 1
- JDMFXJULNGEPOI-UHFFFAOYSA-N 2,6-dichloroaniline Chemical compound NC1=C(Cl)C=CC=C1Cl JDMFXJULNGEPOI-UHFFFAOYSA-N 0.000 description 1
- JFLUVKCJIMSNJM-UHFFFAOYSA-N 2-(1-chlorocyclohexa-2,4-dien-1-yl)-n-(4-chlorophenyl)-n-piperidin-4-ylacetamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N(C(=O)CC1(Cl)C=CC=CC1)C1CCNCC1 JFLUVKCJIMSNJM-UHFFFAOYSA-N 0.000 description 1
- TZIRHFRNVCUQBO-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1Cl TZIRHFRNVCUQBO-UHFFFAOYSA-N 0.000 description 1
- HEHWTBVATBHGPK-UHFFFAOYSA-N 2-(2-piperidin-4-ylphenyl)acetamide Chemical compound N1CCC(CC1)C1=C(C=CC=C1)CC(=O)N HEHWTBVATBHGPK-UHFFFAOYSA-N 0.000 description 1
- CJJURHKDGQSBLE-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C(Cl)=C1 CJJURHKDGQSBLE-UHFFFAOYSA-N 0.000 description 1
- AHGMSTHVQZHTNE-UHFFFAOYSA-N 2-(4-bromophenyl)-n-(4-chlorophenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide Chemical compound C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(Br)C=C1 AHGMSTHVQZHTNE-UHFFFAOYSA-N 0.000 description 1
- HUBPFMHKHROXOZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(2,6-dimethylphenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCC1N(C=1C(=CC=CC=1C)C)C(=O)CC1=CC=C(Cl)C=C1 HUBPFMHKHROXOZ-UHFFFAOYSA-N 0.000 description 1
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- MKBOBWSGAIPQGV-UHFFFAOYSA-N 4-(methoxymethyl)-n-phenyl-1-propan-2-ylpiperidin-4-amine Chemical compound C=1C=CC=CC=1NC1(COC)CCN(C(C)C)CC1 MKBOBWSGAIPQGV-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- DTNMOTLMPKMKPP-UHFFFAOYSA-N [4-(2-chloro-2-oxoethyl)phenyl] ethyl carbonate Chemical compound CCOC(=O)OC1=CC=C(CC(Cl)=O)C=C1 DTNMOTLMPKMKPP-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NIPIVPHWZOGYSP-UHFFFAOYSA-N ethyl 4-(2,6-dichloroanilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=C(Cl)C=CC=C1Cl NIPIVPHWZOGYSP-UHFFFAOYSA-N 0.000 description 1
- FDVHZWJXLOEMLH-UHFFFAOYSA-N ethyl 4-(2,6-dimethylanilino)piperidine-1-carboxylate;hydrochloride Chemical compound Cl.C1CN(C(=O)OCC)CCC1NC1=C(C)C=CC=C1C FDVHZWJXLOEMLH-UHFFFAOYSA-N 0.000 description 1
- LVOOSBDSSQHBOV-UHFFFAOYSA-N ethyl 4-(2,6-dimethylphenyl)iminopiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1=NC1=C(C)C=CC=C1C LVOOSBDSSQHBOV-UHFFFAOYSA-N 0.000 description 1
- KYJAEJLRLOEKSK-UHFFFAOYSA-N ethyl 4-(4-chloro-n-[2-(4-methoxyphenyl)acetyl]anilino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(OC)C=C1 KYJAEJLRLOEKSK-UHFFFAOYSA-N 0.000 description 1
- YWPZNKNNUDFQFZ-UHFFFAOYSA-N ethyl 4-(pyrimidin-2-ylamino)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NC1=NC=CC=N1 YWPZNKNNUDFQFZ-UHFFFAOYSA-N 0.000 description 1
- CPDREELMVQAIKC-UHFFFAOYSA-N ethyl 4-anilino-1-benzylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 CPDREELMVQAIKC-UHFFFAOYSA-N 0.000 description 1
- WGJODELPMZVVJA-UHFFFAOYSA-N ethyl 4-anilino-1-benzylpiperidine-4-carboxylate;dihydrochloride Chemical compound Cl.Cl.C1CC(C(=O)OCC)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 WGJODELPMZVVJA-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- ZNBCKRDKBYESMW-UHFFFAOYSA-N methyl 4-(n-[2-(4-chlorophenyl)acetyl]anilino)-1-propan-2-ylpiperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.C=1C=C(Cl)C=CC=1CC(=O)N(C=1C=CC=CC=1)C1(C(=O)OC)CCN(C(C)C)CC1 ZNBCKRDKBYESMW-UHFFFAOYSA-N 0.000 description 1
- NPNNCHCGYDKUTA-UHFFFAOYSA-N methyl 4-anilino-1-benzylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 NPNNCHCGYDKUTA-UHFFFAOYSA-N 0.000 description 1
- WIYLCEATVIZODY-UHFFFAOYSA-N methyl 4-anilino-1-propan-2-ylpiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1NC1(C(=O)OC)CCN(C(C)C)CC1 WIYLCEATVIZODY-UHFFFAOYSA-N 0.000 description 1
- DVMSHHYWRCBCDO-UHFFFAOYSA-N methyl 4-anilinopiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1NC1(C(=O)OC)CCNCC1 DVMSHHYWRCBCDO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NULMTSYISSJHAI-UHFFFAOYSA-N n,2-bis(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(Cl)C=C1 NULMTSYISSJHAI-UHFFFAOYSA-N 0.000 description 1
- JWZQOGXSBOXWCU-UHFFFAOYSA-N n,2-bis(4-chlorophenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide Chemical compound C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(Cl)C=C1 JWZQOGXSBOXWCU-UHFFFAOYSA-N 0.000 description 1
- CANHHVCOIWZQBM-UHFFFAOYSA-N n,2-bis(4-chlorophenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(Cl)C=C1 CANHHVCOIWZQBM-UHFFFAOYSA-N 0.000 description 1
- CFCQMLAMFCRMIO-UHFFFAOYSA-N n,2-bis(4-chlorophenyl)-n-(1-propylpiperidin-4-yl)acetamide Chemical compound C1CN(CCC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(Cl)C=C1 CFCQMLAMFCRMIO-UHFFFAOYSA-N 0.000 description 1
- XFXULBACFFSBLW-UHFFFAOYSA-N n,2-bis(4-chlorophenyl)-n-piperidin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)N(C=1C=CC(Cl)=CC=1)C1CCNCC1 XFXULBACFFSBLW-UHFFFAOYSA-N 0.000 description 1
- QXQOYULBVHYPAP-UHFFFAOYSA-N n,2-diphenyl-n-(1-propan-2-ylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCC1N(C=1C=CC=CC=1)C(=O)CC1=CC=CC=C1 QXQOYULBVHYPAP-UHFFFAOYSA-N 0.000 description 1
- NTEHWJBQADMGCG-UHFFFAOYSA-N n,n-dimethylformamide;nitrobenzene Chemical compound CN(C)C=O.[O-][N+](=O)C1=CC=CC=C1 NTEHWJBQADMGCG-UHFFFAOYSA-N 0.000 description 1
- AAGNDBZVXDLMJS-UHFFFAOYSA-N n-(1-cyclopentylpiperidin-4-yl)-2-(3-methylphenyl)-n-pyrimidin-2-ylacetamide;oxalic acid Chemical compound OC(=O)C(O)=O.CC1=CC=CC(CC(=O)N(C2CCN(CC2)C2CCCC2)C=2N=CC=CN=2)=C1 AAGNDBZVXDLMJS-UHFFFAOYSA-N 0.000 description 1
- NQCLTKUWOSPQEO-UHFFFAOYSA-N n-(1-propan-2-ylpiperidin-4-yl)pyridin-3-amine Chemical compound C1CN(C(C)C)CCC1NC1=CC=CN=C1 NQCLTKUWOSPQEO-UHFFFAOYSA-N 0.000 description 1
- MBDVECNSKKPYQB-UHFFFAOYSA-N n-(1-propan-2-ylpiperidin-4-yl)pyrimidin-2-amine Chemical compound C1CN(C(C)C)CCC1NC1=NC=CC=N1 MBDVECNSKKPYQB-UHFFFAOYSA-N 0.000 description 1
- IBDXLJBKZTUHHH-UHFFFAOYSA-N n-(1-tert-butylpiperidin-4-yl)-n-(4-chlorophenyl)-2-phenylacetamide;hydrochloride Chemical compound Cl.C1CN(C(C)(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 IBDXLJBKZTUHHH-UHFFFAOYSA-N 0.000 description 1
- KDTLBFKNCWWYHF-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-1-propylpiperidin-4-amine Chemical compound C1CN(CCC)CCC1NC1=C(C)C=CC=C1C KDTLBFKNCWWYHF-UHFFFAOYSA-N 0.000 description 1
- YWPHIVMTOMYUQO-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-phenyl-n-(1-prop-2-enylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1N(C(=O)CC=1C=CC=CC=1)C1CCN(CC=C)CC1 YWPHIVMTOMYUQO-UHFFFAOYSA-N 0.000 description 1
- VUIZXNOFBJYZET-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-phenyl-n-piperidin-4-ylacetamide;hydrobromide Chemical compound Br.CC1=CC=CC(C)=C1N(C(=O)CC=1C=CC=CC=1)C1CCNCC1 VUIZXNOFBJYZET-UHFFFAOYSA-N 0.000 description 1
- MDLLTSLLSQFTBL-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-n-(1-ethylpiperidin-4-yl)-2-phenylacetamide Chemical compound C1CN(CC)CCC1N(C=1C(=CC=CC=1C)C)C(=O)CC1=CC=CC=C1 MDLLTSLLSQFTBL-UHFFFAOYSA-N 0.000 description 1
- MZZFZDBKLAXHTD-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-n-(1-ethylpiperidin-4-yl)-2-thiophen-2-ylacetamide;hydrochloride Chemical compound Cl.C1CN(CC)CCC1N(C=1C(=CC=CC=1C)C)C(=O)CC1=CC=CS1 MZZFZDBKLAXHTD-UHFFFAOYSA-N 0.000 description 1
- GJCQNXTVOLUQGH-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-n-(1-propylpiperidin-4-yl)-2-thiophen-2-ylacetamide Chemical compound C1CN(CCC)CCC1N(C=1C(=CC=CC=1C)C)C(=O)CC1=CC=CS1 GJCQNXTVOLUQGH-UHFFFAOYSA-N 0.000 description 1
- YBORSQLTSFNGCR-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-n-(1-propylpiperidin-4-yl)-2-thiophen-2-ylacetamide;dihydrochloride Chemical compound Cl.Cl.C1CN(CCC)CCC1N(C=1C(=CC=CC=1C)C)C(=O)CC1=CC=CS1 YBORSQLTSFNGCR-UHFFFAOYSA-N 0.000 description 1
- GGZSZUZDQOCVBK-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-n-piperidin-4-yl-2-thiophen-2-ylacetamide Chemical compound CC1=CC=CC(C)=C1N(C(=O)CC=1SC=CC=1)C1CCNCC1 GGZSZUZDQOCVBK-UHFFFAOYSA-N 0.000 description 1
- GCVDVSQZZZAYHM-UHFFFAOYSA-N n-(2,6-dimethylphenyl)piperidin-4-amine Chemical compound CC1=CC=CC(C)=C1NC1CCNCC1 GCVDVSQZZZAYHM-UHFFFAOYSA-N 0.000 description 1
- IDXQVTXVVVODGJ-UHFFFAOYSA-N n-(4-chlorophenyl)-1-prop-2-enylpiperidin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1CCN(CC=C)CC1 IDXQVTXVVVODGJ-UHFFFAOYSA-N 0.000 description 1
- JLLCBWRGOGXRBX-UHFFFAOYSA-N n-(4-chlorophenyl)-1-propan-2-ylpiperidin-4-amine Chemical compound C1CN(C(C)C)CCC1NC1=CC=C(Cl)C=C1 JLLCBWRGOGXRBX-UHFFFAOYSA-N 0.000 description 1
- CFHRNURGSMRQJF-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,4-dichlorophenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide Chemical compound C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(Cl)C(Cl)=C1 CFHRNURGSMRQJF-UHFFFAOYSA-N 0.000 description 1
- PZCLNWWBKSADDQ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3-methoxyphenyl)-n-piperidin-4-ylacetamide Chemical compound COC1=CC=CC(CC(=O)N(C2CCNCC2)C=2C=CC(Cl)=CC=2)=C1 PZCLNWWBKSADDQ-UHFFFAOYSA-N 0.000 description 1
- SZWWWQWPNRMACE-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4-hydroxyphenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(O)C=C1 SZWWWQWPNRMACE-UHFFFAOYSA-N 0.000 description 1
- AUBXDQDEEMAACI-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4-methoxyphenyl)-n-piperidin-4-ylacetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)N(C=1C=CC(Cl)=CC=1)C1CCNCC1 AUBXDQDEEMAACI-UHFFFAOYSA-N 0.000 description 1
- YKJGJUXPUWBJGE-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4-methylphenyl)-n-piperidin-4-ylacetamide Chemical compound C1=CC(C)=CC=C1CC(=O)N(C=1C=CC(Cl)=CC=1)C1CCNCC1 YKJGJUXPUWBJGE-UHFFFAOYSA-N 0.000 description 1
- AMMMXSQOVRPDRJ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(4-propan-2-ylphenyl)-n-(1-propan-2-ylpiperidin-4-yl)acetamide Chemical compound C1CN(C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(C(C)C)C=C1 AMMMXSQOVRPDRJ-UHFFFAOYSA-N 0.000 description 1
- POXIJVKKLNODCS-UHFFFAOYSA-N n-(4-chlorophenyl)-2-phenyl-n-(1-prop-2-enylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N(C(=O)CC=1C=CC=CC=1)C1CCN(CC=C)CC1 POXIJVKKLNODCS-UHFFFAOYSA-N 0.000 description 1
- FSFSWNBDCJVFGI-UHFFFAOYSA-N n-(4-chlorophenyl)-2-phenyl-n-(1-propan-2-ylpiperidin-4-yl)acetamide;hydron;chloride Chemical compound [Cl-].C1C[NH+](C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 FSFSWNBDCJVFGI-UHFFFAOYSA-N 0.000 description 1
- UXSJDOSUZZIRQQ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-phenyl-n-(1-propylpiperidin-4-yl)acetamide;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 UXSJDOSUZZIRQQ-UHFFFAOYSA-N 0.000 description 1
- LYJYBRKNVCVQSM-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-cyclopentylpiperidin-4-yl)-2-phenylacetamide Chemical compound C1=CC(Cl)=CC=C1N(C(=O)CC=1C=CC=CC=1)C1CCN(C2CCCC2)CC1 LYJYBRKNVCVQSM-UHFFFAOYSA-N 0.000 description 1
- RPYGYLFPBYZJTO-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)-2-(3-methylphenyl)acetamide Chemical compound C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC(C)=C1 RPYGYLFPBYZJTO-UHFFFAOYSA-N 0.000 description 1
- HBKKNXYPMVLJNA-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)-2-(4-fluorophenyl)acetamide Chemical compound C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(F)C=C1 HBKKNXYPMVLJNA-UHFFFAOYSA-N 0.000 description 1
- VXORAUIGBVEOOU-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)-2-(4-methylphenyl)acetamide Chemical compound C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=C(C)C=C1 VXORAUIGBVEOOU-UHFFFAOYSA-N 0.000 description 1
- KTJCTQMCOFGIPC-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)-2-phenylacetamide;hydrochloride Chemical compound Cl.C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 KTJCTQMCOFGIPC-UHFFFAOYSA-N 0.000 description 1
- HHYYNYSMYQRWJP-UHFFFAOYSA-N n-(4-chlorophenyl)-n-(1-ethylpiperidin-4-yl)-2-thiophen-2-ylacetamide;hydrochloride Chemical compound Cl.C1CN(CC)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CS1 HHYYNYSMYQRWJP-UHFFFAOYSA-N 0.000 description 1
- GZFOECASLPBAMA-UHFFFAOYSA-N n-(4-chlorophenyl)-n-piperidin-4-yl-2-thiophen-2-ylacetamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1N(C(=O)CC=1SC=CC=1)C1CCNCC1 GZFOECASLPBAMA-UHFFFAOYSA-N 0.000 description 1
- KCOHNRMFXQLTCW-UHFFFAOYSA-N n-(4-chlorophenyl)piperidin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1CCNCC1 KCOHNRMFXQLTCW-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- XSSYIBVJKPNELG-UHFFFAOYSA-N n-[4-(methoxymethyl)-1-propan-2-ylpiperidin-4-yl]-n,2-diphenylacetamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC(=O)N(C=1C=CC=CC=1)C1(COC)CCN(C(C)C)CC1 XSSYIBVJKPNELG-UHFFFAOYSA-N 0.000 description 1
- BGEYIUJJXHLUPW-UHFFFAOYSA-N n-piperidin-4-ylpyrimidin-2-amine;dihydrochloride Chemical compound Cl.Cl.C1CNCCC1NC1=NC=CC=N1 BGEYIUJJXHLUPW-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Foreliggende oppfinnelse angår analogifremgangsmåter for fremstilling av nye, terapeutisk aktive N-aryl-N-(l-lA-4-piperidinyl)-arylacetamider. Tidligere har man oppdaget at noen N-aryl-N-(4-piperidinyl)amider har analgetiske egenskaper. Et antall slike komponenter kan finnes i følgende referanser: US-PS 3.164.600 og The present invention relates to analogue methods for the production of new, therapeutically active N-aryl-N-(1-1A-4-piperidinyl)-arylacetamides. In the past it has been discovered that some N-aryl-N-(4-piperidinyl)amides have analgesic properties. A number of such components can be found in the following references: US-PS 3,164,600 and
CA. , 77, 34349a (1972) . ABOUT. , 77, 34349a (1972).
Blant annet skiller de antiarrytmiske forbindelser i den foreliggende forbindelse seg fra slike kjente forbindelser på den måte hvorved arylacetamidgruppen er knyttet til 4-stillingen i piperidinkjernen. Among other things, the antiarrhythmic compounds in the present compound differ from such known compounds in the manner in which the arylacetamide group is linked to the 4-position in the piperidine nucleus.
De nye N-aryl-N-(l-L^-4-piperidinyl)arylacetamider som fremstilles ifølge foreliggende oppfinnelse kan struktu-relt representeres ved følgende formel: The new N-aryl-N-(1-L^-4-piperidinyl)arylacetamides produced according to the present invention can be structurally represented by the following formula:
og de farmasøytisk akseptable syreaddisjonssalter derav, hvor and the pharmaceutically acceptable acid addition salts thereof, wherein
L^" betyr alkyl med 1-10 karbonatomer, cykloalkyl og cykloalkylalkyl hvor cykloalkyl har 3-6 atomer og alkyl har 1-6 atomer eller alkenyl med 3-6 C-atomer; L^" means alkyl with 1-10 carbon atoms, cycloalkyl and cycloalkylalkyl where cycloalkyl has 3-6 atoms and alkyl has 1-6 atoms or alkenyl with 3-6 C atoms;
Ar betegner fenyl, mono- eller disubstituert fenyl, pyridinyl eller 2-pyrimidinyl, hvori hver substituent i den mono- eller disubstituerte fenyl er halogen eller alkyl med 1-6 karbonatomer; Ar denotes phenyl, mono- or disubstituted phenyl, pyridinyl or 2-pyrimidinyl, in which each substituent in the mono- or disubstituted phenyl is halogen or alkyl with 1-6 carbon atoms;
Ar<1> betyr fenyl, mono- eller disubstituert fenyl, eller tienyl, hvori hver substituent i den mono- eller disubstituerte fenyl er halogen, alkyl med 1-6 karbonatomer, hydroksy eller alkyloksy med 1-6 karbonatomer; og Ar<1> means phenyl, mono- or disubstituted phenyl, or thienyl, wherein each substituent in the mono- or disubstituted phenyl is halogen, alkyl of 1-6 carbon atoms, hydroxy or alkyloxy of 1-6 carbon atoms; and
X betyr hydrogen, alkyloksykarbonyl med 1-6 karbonatomer eller alkyloksymetyl med 1-6 karbonatomer, X means hydrogen, alkyloxycarbonyl with 1-6 carbon atoms or alkyloxymethyl with 1-6 carbon atoms,
hvorved når Ar og Ar"<*>" begge betyr fenyl eller substituert fenyl whereby when Ar and Ar"<*>" both mean phenyl or substituted phenyl
og X betyr hydrogen, kan ikke L<1> bety cykloalkyl med fra 5 - 6 karbonatomer. and X means hydrogen, L<1> cannot mean cycloalkyl with from 5 to 6 carbon atoms.
Forbindelsene med formel (I) kan fremstilles ved The compounds of formula (I) can be prepared by
å innføre en passende L<1->substituent i en passende forbindelse med formel (I-a) introducing a suitable L<1->substituent into a suitable compound of formula (I-a)
i henhold til kjente N-alkyleringsprosedyrer. according to known N-alkylation procedures.
Den nevnte N-alkylering kan enkelt utføres ved å omsette (I-a) med en passende reaktiv ester med formelen L<1->Y, (V), hvor L<1> er som definert ovenfor og hvor Y er en passende reaktiv esterradikal slik som f.eks. halogen eller en sulfonylradikal slik som f.eks. metansulfonyl eller 4-metyl-benzensulfonyl. Den forannevnte reaksjon kan utføres på vanlig måte f.eks. ved å blande reaktantene sammen under til-bakeløpskoking i et passende reaksjonsinert organisk oppløs-ningsmiddel slik som f.eks. en lavere alkanol, f.eks. metanol, etanol, propanol, butanol o.l. alkoholer; et aromatisk hydrokarbon, f.eks. benzen, metylbenzen, dimetyibenzen o.l.; et keton, f.eks. 4-metyl-2-pentanon; en eter, f.eks. 1,4-dioksan, 1,1'-oksybisetan o.l.; N,N-dimetylformamid; nitrobenzen; o.l. For å binde syren som frigjøres under reaksjonen kan det tilsettes en passende base slik som f.eks. natrium eller kaliumkarbonat eller hydrogenkarbonat eller en organisk base, f.eks. N,N-dietyletanamin. En liten mengde alkalimetalljodid, f.eks. kaliumjodid, kan tilsettes for å øke reaksjonshastig-heten særlig når den reaktive ester (V) er et klorid eller bromid. The aforementioned N-alkylation can be easily carried out by reacting (I-a) with a suitable reactive ester of the formula L<1->Y, (V), where L<1> is as defined above and where Y is a suitable reactive ester radical such like for example. halogen or a sulfonyl radical such as e.g. methanesulfonyl or 4-methyl-benzenesulfonyl. The aforementioned reaction can be carried out in the usual way, e.g. by mixing the reactants together under reflux in a suitable reaction-inert organic solvent such as e.g. a lower alkanol, e.g. methanol, ethanol, propanol, butanol etc. alcohols; an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene, etc.; a ketone, e.g. 4-methyl-2-pentanone; an ether, e.g. 1,4-dioxane, 1,1'-oxybisethane and the like; N,N-dimethylformamide; nitrobenzene; beer. To bind the acid released during the reaction, a suitable base can be added, such as e.g. sodium or potassium carbonate or bicarbonate or an organic base, e.g. N,N-Diethylethanamine. A small amount of alkali metal iodide, e.g. potassium iodide, can be added to increase the reaction rate, especially when the reactive ester (V) is a chloride or bromide.
Når L<1> i forbindelsene (I) er alkyl, cykloalkyl eller cykloalkyl-lavere alkyl og når karbonatomet knyttet til nitrogenet i piperidin har minst ett hydrogenatom knyttet til seg, kan innføringen av det nevnte L utføres like enkelt ved ved katalytisk hydrogenering av en blanding av et passende aldehyd eller keton som korresponderer med alkoholen L -0H When L<1> in the compounds (I) is alkyl, cycloalkyl or cycloalkyl-lower alkyl and when the carbon atom linked to the nitrogen in piperidine has at least one hydrogen atom linked to it, the introduction of said L can be carried out just as easily by catalytic hydrogenation of a mixture of an appropriate aldehyde or ketone corresponding to the alcohol L -OH
og en forbindelse med formelen (I-a) i nærvær av en passende katalysator slik som f.eks. palladium-på-kull. For å forbedre selektiviteten i hydrogeneringsreaksjonen kan blandingen tilsettes en liten mengde av en passende katalysatorgift slik som f.eks. tiofen. and a compound of the formula (I-a) in the presence of a suitable catalyst such as e.g. palladium-on-coal. To improve the selectivity in the hydrogenation reaction, a small amount of a suitable catalyst poison can be added to the mixture, such as e.g. thiophene.
Ennå en annen fremgangsmåte for å fremstille forbindelsene med formelen (I) består av å acylere et passende N-aryl-l-L^-4-piperidinamin med formelen (VII) med et passende arylacetylhalogenid med formelen (III) ifølge velkjente N-acyleringsfremgangsmåter som beskrevet ovenfor for fremstillingen av (IV) med utgangspunkt i (II) og (III). Yet another method of preparing the compounds of formula (I) consists of acylating an appropriate N-aryl-1-L^-4-piperidinamine of formula (VII) with an appropriate arylacetyl halide of formula (III) according to well-known N-acylation procedures as described above for the preparation of (IV) starting from (II) and (III).
Acylering av (VII) med (III) kan utføres ved å bruke kjente N-acyleringsfremgangsmåter, f.eks. ved å røre reaktantene sammen og koke under tilbakeløp i et passende reaksjonsinert organisk oppløsningsmiddel, fortrinnsvis i 'nærvær av en passende base. Passende oppløsningsmidler som kan anvendes omfatter f.eks. aromatiske hydrokarboner slik som f.eks. benzen, metylbenzen og dimetylbenzen og haloge-nerte hydrokarboner slik som triklormetan. Passende baser omfatter f.eks. alkalimetallkarbonater og hydrogenkarbonater, <1>alkalimetallamider slik som natriumamid, og organiske baser slik som f.eks. pyridin og N,N-dietyletanamin. Acylation of (VII) with (III) can be carried out using known N-acylation procedures, e.g. by stirring the reactants together and refluxing in a suitable reaction-inert organic solvent, preferably in the presence of a suitable base. Suitable solvents that can be used include e.g. aromatic hydrocarbons such as e.g. benzene, methylbenzene and dimethylbenzene and halogenated hydrocarbons such as trichloromethane. Suitable bases include e.g. alkali metal carbonates and hydrogen carbonates, <1>alkali metal amides such as sodium amide, and organic bases such as e.g. pyridine and N,N-diethylethanamine.
Når Ar<1> i forbindelsene (I) er en substituert fenyl-gruppe som som substituenter har én eller to hydroksylgrupper alene eller sammen med andre substituenter, er det påkrevet å beskytte de nevnte hydroksylgrupper i de korresponderende utgangsmaterialer (III) med en passende beskyttelsesgruppe slik som et lavere alkyloksykarbonyl, hvoretter et korresponderende derivat av (I) tilveiebringes og beskyttelsesgruppen fjernes lett ved alkalisk hydrolyse under anvendelse av f.eks. fortynnet vandig alkali. When Ar<1> in the compounds (I) is a substituted phenyl group which has as substituents one or two hydroxyl groups alone or together with other substituents, it is required to protect the said hydroxyl groups in the corresponding starting materials (III) with a suitable protecting group such as a lower alkyloxycarbonyl, after which a corresponding derivative of (I) is provided and the protecting group is easily removed by alkaline hydrolysis using e.g. dilute aqueous alkali.
Forbindelsen ifølge oppfinnelsen kan omdannes til farmasøytisk akseptable syreaddisjonssalter ved behandling med en passende syre slik som f.eks. en uorganisk syre som en hydrohalogensyre, f.eks. saltsyre, hydrobromsyre o.l. og svovelsyre, salpetersyre, fosforsyre o.l., eller en organisk syre slik som f.eks. eddiksyre, propanonsyre, 2-hydroksy-eddiksyre, 2-hydroksypropanonsyre, 2-oksopropanonsyre, propa-nondionsyre, butandionsyre, (Z)-2-butendionsyre, (E)-2-buten-dionsyre, 2-hydroksybutandionsyre, 2,3-dihydroksybutandion-syre, 2-hydroksyl-l,2,3-propantrikarboksylsyre, benzosyre, 3-fenyl-2-propenonsyre, a-hydroksybenzeneddiksyre, metansulfon-syre, etansulfonsyre, benzensulfonsyre, 4-metylbenzensulfonsyre, cykloheksansulfaminsyre, 2-hydroksybenzosyre, 4-amino-2-hydroksybenzosyre o.l. syrer. Saltformen kan omdannes til den frie base ved behandling med alkali. The compound according to the invention can be converted into pharmaceutically acceptable acid addition salts by treatment with a suitable acid such as e.g. an inorganic acid such as a hydrohalic acid, e.g. hydrochloric acid, hydrobromic acid, etc. and sulfuric acid, nitric acid, phosphoric acid etc., or an organic acid such as e.g. acetic acid, propanoic acid, 2-hydroxy-acetic acid, 2-hydroxypropanonic acid, 2-oxopropanonic acid, propanonedioic acid, butanedioic acid, (Z)-2-butenedioic acid, (E)-2-butenedioic acid, 2-hydroxybutanedioic acid, 2,3- dihydroxybutanedione acid, 2-hydroxyl-1,2,3-propanetricarboxylic acid, benzoic acid, 3-phenyl-2-propenonic acid, α-hydroxybenzeneacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, cyclohexanesulfamic acid, 2-hydroxybenzoic acid, 4- amino-2-hydroxybenzoic acid, etc. acids. The salt form can be converted to the free base by treatment with alkali.
Mellomproduktene anvendt som utgangsmaterialer i de forangående fremstillinger, hvorav flere er kjente forbindelser, kan fremstilles på følgende måte: The intermediate products used as starting materials in the preceding preparations, several of which are known compounds, can be prepared in the following way:
Mellomproduktene med formelen (I-a) kan vanligvis fremstilles ved å ta utgangspunkt i et piperidinderivat med formel (II) hvor Ar og X er som tidligere definert og hvor P er en passende beskyttelsesgruppe såsom f.eks. fenylmetyl, lavere alkyloksykarbonyl eller et fenylmetoksykarbonyl ved først å acylere (II) med et passende arylacetylhalogenid med formel (III) og da fortrinnsvis kloridet for deretter å eliminere beskyttelsesgruppen P av det på denne måte tilveiebragte (IV) ved i og for seg kjente fremgangsmåter: The intermediates of formula (I-a) can usually be prepared by starting from a piperidine derivative of formula (II) where Ar and X are as previously defined and where P is a suitable protecting group such as e.g. phenylmethyl, lower alkyloxycarbonyl or a phenylmethoxycarbonyl by first acylating (II) with a suitable arylacetyl halide of formula (III) and then preferably the chloride to then eliminate the protecting group P of the thus obtained (IV) by methods known per se:
Elimineringen av beskyttelsesgruppen P kan utføres ved kjente fremgangsmåter. Når beskyttelsesgruppen er fenylmetyl eller fenylmetoksykarbonyl, kan den lett fjernes ved katalytisk hydrogenering under anvendelse av en passende katalysator, f.eks. palladium-på-kull, og når beskyttelsesgruppen er lavere alkyloksykarbonyl, kan elimineringen lett utføres under anvendelse av en sterk mineralsyre, f.eks. saltsyre, hydrobromsyre eller svovelsyre, og alkalisk hydrolyse utføres lett ved å anvende alkoholisk alkali, f.eks. kaliumhydroksyd i 2-propanol. The elimination of the protecting group P can be carried out by known methods. When the protecting group is phenylmethyl or phenylmethoxycarbonyl, it can be readily removed by catalytic hydrogenation using a suitable catalyst, e.g. palladium-on-charcoal, and when the protecting group is lower alkyloxycarbonyl, the elimination can easily be carried out using a strong mineral acid, e.g. hydrochloric acid, hydrobromic acid or sulfuric acid, and alkaline hydrolysis is easily carried out by using alcoholic alkali, e.g. potassium hydroxide in 2-propanol.
Mellomproduktene med formel (II) hvor X er hydrogen, (II-a), fremstilles enkelt på følgende måte. Et 4-piperidin-on med formelen (VIII) som i 1-stilling har en passende beskyttelsesgruppe P, underkastes en kondensasjonsreaksjon med et passende arylamin (IX) f.eks. ved å koke reaktantene under tilbakeløp under omrøring med azeotrop vannfjerning i et passende organisk oppløsningsmiddel, fortrinnsvis et aromatisk hydrokarbon slik som benzen, metylbenzen eller dimetylbenzen, i nærvær av en passende syre slik som f.eks. 4-metylbenzensulfonsyre, eddiksyre, saltsyre o.l. Den resulterende Schiffske base (X) reduseres deretter med et passende reduksjonsmiddel slik som f.eks. natriumborhydrid eller ved katalytisk hydrogenering under anvendelse av f.eks. platinumoksydkatalysator for å tilveiebringe det korresponderende N-aryl-4-piperidin-amin (II-a). The intermediate products of formula (II) where X is hydrogen, (II-a), are easily prepared in the following way. A 4-piperidin-one of the formula (VIII) which in the 1-position has a suitable protecting group P, is subjected to a condensation reaction with a suitable arylamine (IX) e.g. by refluxing the reactants with stirring with azeotropic water removal in a suitable organic solvent, preferably an aromatic hydrocarbon such as benzene, methylbenzene or dimethylbenzene, in the presence of a suitable acid such as e.g. 4-methylbenzenesulfonic acid, acetic acid, hydrochloric acid, etc. The resulting Schiff base (X) is then reduced with a suitable reducing agent such as e.g. sodium borohydride or by catalytic hydrogenation using e.g. platinum oxide catalyst to provide the corresponding N-aryl-4-piperidine-amine (II-a).
De forannevnte reaksjoner illustreres klarere ved følgende reaksjonsskjerna: The aforementioned reactions are illustrated more clearly by the following reaction nucleus:
Mellomprodukter med formel (VII) hvor X er hydrogen, (VII-a), fremstilles enkelt ved å gå ut fra (II-a) ved først å eliminere beskyttelsesgruppen P på vanlig måte for å tilveiebringe et N-aryl-4-piperidinamin med formelen (XI) og deretter innføres L^-substituenten som beskrevet foran, for fremstilling av (I) med utgangspunkt i (I-a). Intermediates of formula (VII) where X is hydrogen, (VII-a), are easily prepared starting from (II-a) by first eliminating the protecting group P in the usual manner to provide an N-aryl-4-piperidinamine with the formula (XI) and then the L^-substituent is introduced as described above, for the preparation of (I) starting from (I-a).
Når L i mellomproduktene (VII-a) er en metylgruppe, (VII-a-1), kan de tilveiebringes direkte ved en reduksjon av mellomproduktet (II-a) hvor P er en lavere alkyloksykarbonyl-gruppe, (II-a-2), med et passende reduksjonsmiddel slik som f.eks. litiumaluminiumhydrid. De forannevnte reaksjoner illustreres ved følgende reaksjonsskjerna: When L in the intermediates (VII-a) is a methyl group, (VII-a-1), they can be provided directly by a reduction of the intermediate (II-a) where P is a lower alkyloxycarbonyl group, (II-a-2 ), with a suitable reducing agent such as e.g. lithium aluminum hydride. The aforementioned reactions are illustrated by the following reaction nucleus:
Mellomprodukter med formel (II) hvor X er lavere alkoksykarbonyl, (II-b), kan fremstilles på følgende måte: 1-fenylmetyl-4-piperidinon (XII) omsettes med et passende arylamin (IX) og et alkalimetallcyanid, f.eks. kali-umcyanid i et vandig organisk karboksylsyresystem slik som eddiksyre eller en vandig lavere alkanol i nærvær av en ekvivalent av en uorganisk .syre slik som saltsyre hvorved inn-føringen av nitrilfunksjonen og aminfunksjonen utføres i 4-stilling i piperidinkjernen, noe som gir et mellomprodukt med formelen (XIII). Intermediates of formula (II) where X is lower alkoxycarbonyl, (II-b), can be prepared in the following way: 1-phenylmethyl-4-piperidinone (XII) is reacted with a suitable arylamine (IX) and an alkali metal cyanide, e.g. potassium cyanide in an aqueous organic carboxylic acid system such as acetic acid or an aqueous lower alkanol in the presence of an equivalent of an inorganic acid such as hydrochloric acid whereby the introduction of the nitrile function and the amine function is carried out in the 4-position of the piperidine nucleus, giving an intermediate with the formula (XIII).
Nitrilet (XIII) omdannes deretter til amidet (XIV) ved syrehydrolyse. Man kan med fordel anvende en konsentrert sterk, vandig, uorganisk syre for dette formål slik som saltsyre, fosforsyre og fortrinnsvis svovelsyre. Amidet (XIV) hydrolyseres ytterligere for å tilveiebringe den korresponderende karboksylsyre (XV) ved å anvende de kjente amid-til-syre-hydrolysemetoder, f.eks. ved å behandle (XIV) med en fortynnet sterk syre, f.eks. saltsyre eller svovelsyre eller ved alkalisk hydrolyse under anvendelse av en passende base, f.eks. natrium- eller kaliumhydroksyd. Den tilveiebragte karboksylsyre (XV) omdannes i sin tur til metallsaltet av denne, fortrinnsvis natriumsaltet (XVI), ved omsetning med alkali, f.eks. natriumhydroksyd. Karboksylsyren (XV) behøver ikke nødvendig-vis isoleres eller renses, men kan anvendes som en urenset blanding for fremstillingen av (XVI), eller saltet kan tilveiebringes direkte når den alkaliske hydrolyse utføres. The nitrile (XIII) is then converted to the amide (XIV) by acid hydrolysis. A concentrated strong, aqueous, inorganic acid can advantageously be used for this purpose, such as hydrochloric acid, phosphoric acid and preferably sulfuric acid. The amide (XIV) is further hydrolysed to provide the corresponding carboxylic acid (XV) using the known amide-to-acid hydrolysis methods, e.g. by treating (XIV) with a dilute strong acid, e.g. hydrochloric or sulfuric acid or by alkaline hydrolysis using a suitable base, e.g. sodium or potassium hydroxide. The provided carboxylic acid (XV) is in turn converted into its metal salt, preferably the sodium salt (XVI), by reaction with alkali, e.g. sodium hydroxide. The carboxylic acid (XV) does not necessarily need to be isolated or purified, but can be used as an impure mixture for the preparation of (XVI), or the salt can be provided directly when the alkaline hydrolysis is carried out.
Saltet (XVI) omdannes deretter til den ønskede The salt (XVI) is then converted into the desired one
ester (II-b) hvor P er fenylmetyl (II-b-1) ved omsetning med et passende halogen-lavere alkan (XVII) i et passende oppløsningsmiddel slik som f.eks. heksametylfosfortriamid. ester (II-b) where P is phenylmethyl (II-b-1) by reaction with a suitable halogen-lower alkane (XVII) in a suitable solvent such as e.g. hexamethylphosphoric triamide.
De forannevnte reaksjoner illustreres klarere ved følgende reaksjonsskjema: The aforementioned reactions are illustrated more clearly by the following reaction scheme:
Mellomproduktene med formelen (II-b) hvor P er lavere alkyloksykarbonyl eller fenylmetoksykarbonyl (II-b-2) fremstilles lett fra (II-b-1) ved å eliminere den beskyttende fenylmetyl-gruppe og deretter innføre i det på denne måte tilveiebragte (XIX) den lavere alkyloksykarbonyl- eller fenylmetoksykarbonyl-gruppe ifølge kjente fremgangsmåter f.eks. ved å omsette f.eks. The intermediates of the formula (II-b) where P is lower alkyloxycarbonyl or phenylmethoxycarbonyl (II-b-2) are easily prepared from (II-b-1) by eliminating the protecting phenylmethyl group and then introducing into the thus obtained ( XIX) the lower alkyloxycarbonyl or phenylmethoxycarbonyl group according to known methods, e.g. by converting e.g.
(XIX) med et passende lavere alkyl eller fenylmetylkarbonhalidat eller direkte ved å omsette (II-b-1) med et lavere alkyl eller fenylmetylkarbonhalidat hvoretter fenylmetylgruppen i (II-b-1) erstattes med den ønskede lavere alkyloksykarbonyl-eller fenyl-metoksykarbonylgruppe. (XIX) with a suitable lower alkyl or phenylmethylcarbonhalidate or directly by reacting (II-b-1) with a lower alkyl or phenylmethylcarbonhalidate after which the phenylmethyl group in (II-b-1) is replaced by the desired lower alkyloxycarbonyl or phenylmethoxycarbonyl group.
Mellomproduktene med formelen (VII) hvor X er lavere alkyloksykarbonyl (VII-b) fremstilles hensiktsmessig ved å inn-føre L "''-gruppen i et mellomstoff (XIX) ifølge de fremgangsmåter som er beskrevet ovenfor. The intermediates of the formula (VII) where X is lower alkyloxycarbonyl (VII-b) are suitably prepared by introducing the L "'' group into an intermediate (XIX) according to the methods described above.
Mellomproduktene med formelen (II) og (VII) hvor X er lavere alkyloksymetyl, (II-c) og (VII-c) kan fremstilles på følgende måte: En passende lavere alkylester med formelen (II-b) reduseres med et passende reduseringsmiddel slik som f.eks. natriumdihydro-bis(2-metoksyetoksy)aluminat (Red-Al) i et passende organisk oppløsningsmiddel slik som f.eks. benzen eller med litiumborhydrid for å tilveiebringe 4-piperidinmetanol med formelen (XX). Det nevnte (XX) underkastes en O-alkylerings-reaksjon med et passende alkyleringsmiddel. O-alkyleringstrinnet kan utføres ved å omsette (XX) med et passende halogen-lavere alkan eller di-(lavere alkyl)sulfat i et passende organisk opp-løsningsmiddel slik som f.eks. benzen, metylbenzen, dimetylbenzen, tetrahydrofuran o.l. i nærvær av et passende kvaternært ammoniumsalt slik som N,N,N-trietylbenzenmetanaminiumklorid noe som gir det ønskede mellomstoff (II-c). Mellomproduktene The intermediates of the formula (II) and (VII) where X is lower alkyloxymethyl, (II-c) and (VII-c) can be prepared as follows: A suitable lower alkyl ester of the formula (II-b) is reduced with a suitable reducing agent as like for example. sodium dihydro-bis(2-methoxyethoxy)aluminate (Red-Al) in a suitable organic solvent such as e.g. benzene or with lithium borohydride to provide 4-piperidinemethanol of formula (XX). The aforementioned (XX) is subjected to an O-alkylation reaction with a suitable alkylating agent. The O-alkylation step can be carried out by reacting (XX) with a suitable halogen-lower alkane or di-(lower alkyl)sulphate in a suitable organic solvent such as e.g. benzene, methylbenzene, dimethylbenzene, tetrahydrofuran, etc. in the presence of a suitable quaternary ammonium salt such as N,N,N-triethylbenzenemethanaminium chloride which gives the desired intermediate (II-c). The intermediate products
(VII-c) kan fremstilles ved først å eliminere beskyttelsesgruppen i (II-c) og deretter innføre L<1->substituenten i det på denne måte tilveiebragte mellomstoff (XXI) ifølge de fremgangsmåter som er beskrevet tidligere. (VII-c) can be prepared by first eliminating the protecting group in (II-c) and then introducing the L<1->substituent in the thus obtained intermediate (XXI) according to the methods described earlier.
Ellers kan mellomproduktene (VII-c) også fremstilles ved å redusere en passende alkylester med formelen (VII-b) til det korresponderende 4-piperidinmetanol (XXII) på tilsvarende måte som beskrevet ovenfor for fremstilling av (XX) med utgangspunkt (II-b), for deretter å underkaste (XXII) en O-alkyl-eringsreaksjon med et passende lavere alkyleringsmiddel ifølge de fremgangsmåter som er angitt for å fremstille (II-c) med utgangspunkt i (XX). Otherwise, the intermediates (VII-c) can also be prepared by reducing a suitable alkyl ester with the formula (VII-b) to the corresponding 4-piperidinemethanol (XXII) in a similar way as described above for the preparation of (XX) starting from (II-b ), to then subject (XXII) to an O-alkylation reaction with a suitable lower alkylating agent according to the methods indicated to prepare (II-c) starting from (XX).
De forannevnte fremgangsmåter er illustrert i The aforementioned methods are illustrated in
det etterfølgende: the following:
Forbindelsene med formelen (I) og deres farmasøy-tisk akseptable syreaddisjonssalter viser utmerkede antiarrytmetiske egenskaper og de er nyttige for å normalisere uregel-messige hjerterytmer. Den antiarrytmetiske effekt i forbindelsene ifølge oppfinnelsen illustreres ved det følgende eksperiment med hunder. The compounds of formula (I) and their pharmaceutically acceptable acid addition salts exhibit excellent antiarrhythmic properties and are useful in normalizing irregular heart rhythms. The antiarrhythmic effect in the compounds according to the invention is illustrated by the following experiment with dogs.
Prøvene ble utført under neuroleptanalgesia The tests were performed under neuroleptanalgesia
(1 ml/10 kg kroppsvekt av fentanyl (N-fenyl-N-[1-(2-fenyl-etyl)-4-piperidinyl]propanamid) (0,4 mg/ml) og droperidol (1-[1-[4-(4-fluorfenyl)-4-oksobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-2H-benzimidazol-2-on) (20 mg/ml)). Ca. 16 timer etter avsnøring av den bakre nedstigende gren av den venstre koronararterie utviste hundene en multifokal ventrikulær arrytmi. (1 ml/10 kg body weight of fentanyl (N-phenyl-N-[1-(2-phenyl-ethyl)-4-piperidinyl]propanamide) (0.4 mg/ml) and droperidol (1-[1-[ 4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-2H-benzimidazol-2-one) (20 mg/ml)). About. 16 hours after ligation of the posterior descending branch of the left coronary artery, the dogs exhibited a multifocal ventricular arrhythmia.
Prøveforbindelsene ble gitt intravenøst etter en kontrollperiode på 30 min., og man anla følgende kriterier: The test compounds were administered intravenously after a control period of 30 min., and the following criteria were applied:
0 : ingen virkning. 0 : no effect.
+ : reduksjon av antall for tidlige slag og en økning av antall normale slag med minst 30% sammenlignet med kontrollverdien. + : reduction of the number of premature beats and an increase of the number of normal beats by at least 30% compared to the control value.
++ : reduksjon av antall for tidlige slag og en økning av antall normale slag med minst 50% sammenlignet med kontrollverdien. ++ : reduction of the number of premature beats and an increase of the number of normal beats by at least 50% compared to the control value.
+++ : normalisering av hjerterytmen eller reduksjon av antall for tidlige slag og antall normale slag med minst 75% sammenlignet med kontrollverdien. +++ : normalization of the heart rhythm or reduction of the number of premature beats and the number of normal beats by at least 75% compared to the control value.
Resultatene i dette eksperiment er gjengitt i de etterfølgende tabeller. The results of this experiment are reproduced in the following tables.
For sammenligningens skyld er det gjennomført for-søk med den forbindelse som er beskrevet i krav 2 i US-PS 3.869.463, også kjent som compound R 5630. Disse forsøk gir som konklusjon at compound R 5630 er totalt inaktiv, selv ved usedvanlig høye doseringer, i den prøve som her er beskrevet . For the sake of comparison, trials have been carried out with the compound described in claim 2 of US-PS 3,869,463, also known as compound R 5630. These trials conclude that compound R 5630 is totally inactive, even at exceptionally high dosages, in the sample described here.
De følgende eksempler illustrerer oppfinnelsen. Dersom ikke annet er angitt, er alle deler vektdeler. The following examples illustrate the invention. Unless otherwise stated, all parts are parts by weight.
Eksemplene I til XXIX beskriver fremstilling av mellomprodukter. Examples I to XXIX describe the preparation of intermediates.
Eksempel I Example I
En blanding av 19 deler 1-(fenylmetyl)-4-piperi-dinon, 11,8 deler 3-pyridinamin, 120 deler metylbenzen og en liten mengde 4-metylbenzensulfonsyre omrøres og kokes under til-bakeløp i 5 timer. (Reaksjonskaret er utstyrt med en tilbake-løpskjøler og en vannseparator). Etter at den beregnede mengde vann er utskilt fordampes oppløsningsmidlet. Den oljeaktige rest oppløses i 800 deler 2,2<1->oksybispropan og fordampes igjen noe som gir 27 deler N-[1-fenylmetyl)-4-piperidinyliden]-3-pyridinamin som en gulbrun olje. A mixture of 19 parts of 1-(phenylmethyl)-4-piperidinone, 11.8 parts of 3-pyridinamine, 120 parts of methylbenzene and a small amount of 4-methylbenzenesulfonic acid is stirred and refluxed for 5 hours. (The reaction vessel is equipped with a reflux condenser and a water separator). After the calculated amount of water has been separated, the solvent is evaporated. The oily residue is dissolved in 800 parts of 2,2<1->oxybispropane and evaporated again which gives 27 parts of N-[1-phenylmethyl)-4-piperidinylidene]-3-pyridinamine as a yellow-brown oil.
Til en omrørt oppløsning av 27 deler N-[l- (fenylmetyl) -4-piperidinyliden]-3-pyridinamin i 40 deler etanol tilsettes porsjonsvis 3,8 deler natriumborhydrid. Etterat tilsatsen er fullstendig oppvarmes blandingen til 50°C. Oppløsnings-midlet fordampes. Den oljeaktige rest oppløses i 150 deler saltsyre IN og filtreres. Filtratet gjøres alkalisk med ammoniumhydroksyd og ekstraheres med metylbenzen. Det organiske lag tørkes over magnesiumsulfat, filtreres og fordampes. Den faste rest vaskes med 2,2'-oksybispropan og tørkes noe som gir 14 deler N-[1-(fenylmetyl)-4-piperidinyl]-3-pyridinamin med smeltepunkt 131-133°C som et beige, amorft pulver. To a stirred solution of 27 parts of N-[1-(phenylmethyl)-4-piperidinylidene]-3-pyridinamine in 40 parts of ethanol, 3.8 parts of sodium borohydride are added in portions. After the addition is complete, the mixture is heated to 50°C. The solvent is evaporated. The oily residue is dissolved in 150 parts hydrochloric acid IN and filtered. The filtrate is made alkaline with ammonium hydroxide and extracted with methylbenzene. The organic layer is dried over magnesium sulphate, filtered and evaporated. The solid residue is washed with 2,2'-oxybispropane and dried which gives 14 parts of N-[1-(phenylmethyl)-4-piperidinyl]-3-pyridinamine with melting point 131-133°C as a beige, amorphous powder.
En blanding av 20 deler N-[1-(fenylmetyl)-4-piper-idinyl ] -3-pyridinamin , 160 deler metanol, 30 deler vann og 12 deler konsentrert saltsyreoppløsning hydrogeneres ved normalt trykk og med en temperatur på mellom 22 og 39°C, i nærvær av 7 deler palladium-på-kullkatalysator 10%. Etterat den beregnede mengde hydrogen er tatt opp, stoppes hydrogeneringen. Katalysatoren frafiltreres, og filtratet fordampes. Den oljeaktige rest oppløses i vann. Denne oppløsning gjøres alkalisk med ammoniumhydroksyd, mettes med fast kaliumkarbonat og ekstraheres deretter med metylbenzen. Ekstraktet tørkes over kaliumkarbonat og fordampes. -Den faste rest rekrystalliseres fra en blanding av 40 deler benzen og 32 deler 1,1<1->oksybisetan, noe som gir 3 deler N-(4-piperidinyl)-3-pyridinamin med et smeltepunkt på 127-129°C. A mixture of 20 parts N-[1-(phenylmethyl)-4-piperidinyl]-3-pyridinamine, 160 parts methanol, 30 parts water and 12 parts concentrated hydrochloric acid solution is hydrogenated at normal pressure and with a temperature between 22 and 39 °C, in the presence of 7 parts palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen has been taken up, the hydrogenation is stopped. The catalyst is filtered off, and the filtrate is evaporated. The oily residue dissolves in water. This solution is made alkaline with ammonium hydroxide, saturated with solid potassium carbonate and then extracted with methylbenzene. The extract is dried over potassium carbonate and evaporated. -The solid residue is recrystallized from a mixture of 40 parts of benzene and 32 parts of 1,1<1->oxybisethane, which gives 3 parts of N-(4-piperidinyl)-3-pyridinamine with a melting point of 127-129°C.
Eksempel II Example II
En blanding av 171,2 deler etyl 4-okso-l-piperidinkarboksylat, 159,5 deler 4-klorbenzenamin, 1520 deler vann-fri metylbenzen og noen få krystaller 4-metylbenzensulfonsyre omrøres og kokes under tilbakeløp i 7 timer. (Reaksjonskaret er utstyrt med en tilbakeløpskjøler og en vannseparator). Met-ylbenzenet fordampes og den oljeaktige rest destilleres i vakuum noe som gir 192 deler av oljeaktig etyl 4-[(4-klorfenyl)imino]-1-piperidinkarboksylat med kokepunkt 171-176°C ved 0,4 mm trykk. A mixture of 171.2 parts of ethyl 4-oxo-1-piperidinecarboxylate, 159.5 parts of 4-chlorobenzenamine, 1520 parts of anhydrous methylbenzene and a few crystals of 4-methylbenzenesulfonic acid is stirred and refluxed for 7 hours. (The reaction vessel is equipped with a reflux cooler and a water separator). The methylbenzene is evaporated and the oily residue is distilled in vacuum, which gives 192 parts of oily ethyl 4-[(4-chlorophenyl)imino]-1-piperidine carboxylate with boiling point 171-176°C at 0.4 mm pressure.
Eksempel III Example III
Ved å gjenta fremgangsmåten fra eks. II og ved å bruke ekvivalente mengder av et passende arylamin istedenfor 4-klorbenzenamin fremstilles følgende forbindelser: By repeating the procedure from e.g. II and using equivalent amounts of a suitable arylamine instead of 4-chlorobenzenamine, the following compounds are prepared:
Eksempel IV Example IV
En blanding av 171 deler etyl-4-okso-l-piperidinkarboksylat, 162 deler 2,6-diklorbenzenamin, 800 deler dimetylbenzen og 1 del 4-metylbenzensulfonsyre omrøres og kokes under tilbakeløp med vannseparator. Reaksjonsblandingen fordampes, noe som gir 250 deler etyl-4-[(2,6-diklorfenyl)imino]-1-piperidinkarboksylat som en rest. A mixture of 171 parts of ethyl 4-oxo-1-piperidine carboxylate, 162 parts of 2,6-dichlorobenzeneamine, 800 parts of dimethylbenzene and 1 part of 4-methylbenzenesulfonic acid is stirred and refluxed with a water separator. The reaction mixture is evaporated, giving 250 parts of ethyl 4-[(2,6-dichlorophenyl)imino]-1-piperidinecarboxylate as a residue.
Eksempel V Example V
Til en varm oppløsning av 192 deler etyl-4-[(4-klorfenyl)-imino]-1-piperidinkarboksylat i 560 deler metanol tilsettes porsjonsvis 23,5 deler natriumborhydrid ved 50°C i løpet av 1 time. Etterat tilsatsen er avsluttet, omrøres blandingen ved samme temperatur i 2 timer. Metanolen fordampes. To a hot solution of 192 parts of ethyl 4-[(4-chlorophenyl)-imino]-1-piperidinecarboxylate in 560 parts of methanol, 23.5 parts of sodium borohydride are added in portions at 50°C over the course of 1 hour. After the addition has ended, the mixture is stirred at the same temperature for 2 hours. The methanol evaporates.
Den faste rest oppvarmes med ca. 600 deler vann og produktet ekstraheres med benzen. Ekstraktet tørkes over magnesiumsulfat og fordampes. Den oljeaktige rest stivner ved behandling med 2,2'-oksybispropan. Det faste stoff frafiltreres og tørkes noe som gir 122 deler etyl-4-[(4-klorfenyl)amino]-1-piperidinkarboksylat med smeltepunkt 115-118°C. The solid residue is heated with approx. 600 parts water and the product is extracted with benzene. The extract is dried over magnesium sulfate and evaporated. The oily residue solidifies when treated with 2,2'-oxybispropane. The solid is filtered off and dried, which gives 122 parts of ethyl 4-[(4-chlorophenyl)amino]-1-piperidine carboxylate with a melting point of 115-118°C.
Eksempel VI Example VI
Under anvendelse av den fremgangsmåte som er Using the method that is
gitt i eks. V og ved å bruke en ekvivalent mengde av et passende etyl-4-arylimino-l-piperidinkarboksylat, fremstilles følg-ende forbindelser: given in ex. V and using an equivalent amount of an appropriate ethyl 4-arylimino-1-piperidine carboxylate, the following compounds are prepared:
Eksempel VII Example VII
Til en omrørt oppløsning som kokes under tilbake-løp av 250 deler etyl-4-[(2,6-diklorfenyl)imino]-1-piperidinkarboksylat i 160 deler metanol og 160 deler 2-propanol tilsettes porsjonsvis 30 deler natriumborhydrid. Etter at tilsatsen er avsluttet, fortsettes omrøringen ved tilbakeløpstemperaturen i 1 time. Den varme reaksjonsblanding helles over i vann og produktet ekstraheres med metylbenzen. Ekstraktet tørkes og fordampes. Resten krystalliseres fra en blanding av 160 deler 2,2'-oksybispropan og 160 deler petroleter noe som gir 96 deler etyl-4-[(2,6-diklorfenyl)amino]-1-piperidinkarboksylat med smeltepunkt 107,2-116,6°C. 30 parts of sodium borohydride are added in portions to a stirred solution which is boiled under reflux of 250 parts of ethyl 4-[(2,6-dichlorophenyl)imino]-1-piperidine carboxylate in 160 parts of methanol and 160 parts of 2-propanol. After the addition has ended, stirring is continued at the reflux temperature for 1 hour. The hot reaction mixture is poured into water and the product is extracted with methylbenzene. The extract is dried and evaporated. The residue is crystallized from a mixture of 160 parts of 2,2'-oxybispropane and 160 parts of petroleum ether, which gives 96 parts of ethyl 4-[(2,6-dichlorophenyl)amino]-1-piperidine carboxylate with a melting point of 107.2-116.6 °C.
Eksempel VIII Example VIII
En blanding av 45 deler etyl-4-[(2,6-dimetylfenyl)-imino]-1-piperidinkarboksylat, 0,3 deler platinumdioksyd i 160 deler metanol hydrogeneres ved normalt trykk og ved en temperatur på mellom 24 og 35°C. Etterat den beregnede mengde hydrogen er tatt opp, stoppes hydrogeneringen. Katalysatoren frafiltreres og filtratet fordampes. Den oljeaktige rest destilleres noe som gir 30 deler av en oljeaktig fri base av etyl-4-[(2,6-dimetylfenyl)amino]-1-piperidinkarboksylat med smeltepunkt 148-153°C ved 0,01 mm trykk. Fra dette destillat fremstilles hydrokloridsaltet på vanlig måte i 1,1<1->oksybisetan. Det utfelte faste salt frafiltreres og tørkes noe som gir 28,5 deler etyl-4-[(2,6-dimetylfenyl)amino]-1-piperidinkarboksylathydro-klorid med smeltepunkt 195,5°C. A mixture of 45 parts of ethyl 4-[(2,6-dimethylphenyl)-imino]-1-piperidinecarboxylate, 0.3 parts of platinum dioxide in 160 parts of methanol is hydrogenated at normal pressure and at a temperature of between 24 and 35°C. After the calculated amount of hydrogen has been taken up, the hydrogenation is stopped. The catalyst is filtered off and the filtrate is evaporated. The oily residue is distilled which gives 30 parts of an oily free base of ethyl 4-[(2,6-dimethylphenyl)amino]-1-piperidinecarboxylate with melting point 148-153°C at 0.01 mm pressure. From this distillate, the hydrochloride salt is prepared in the usual way in 1,1<1->oxybisethane. The precipitated solid salt is filtered off and dried, which gives 28.5 parts of ethyl 4-[(2,6-dimethylphenyl)amino]-1-piperidinecarboxylate hydrochloride with a melting point of 195.5°C.
En blanding av 10 deler etyl-4-[(2,6-dimetylfenyl)-amino]-1-piperidinkarboksylat og 135 deler hydrobromsyreopp-løsning 48% omrøres ved en temperatur på mellom 80 og 110°C inntil utviklingen av gassformet karbondioksyd er slutt (etter ca. 1 time). Den rødfargede reaksjonsblanding fordampes i vakuum. Resten tas opp i 56 deler metylbenzen og den sistnevnte fordampes igjen. Fordampingen gjentas i en blanding av 24 deler 2-propanon og 40 deler metylbenzen. Den resulterende halvfaste rest tritureres i 80 deler varm 2-propanon og ved avkjøling utfelles det faste produkt. Det frafiltreres og vaskes henholdsvis med små mengder absolutt etanol og 2-propanon og tørkes noe som gir 13 deler N-(2,6-dimetylfenyl)-4-piperi- A mixture of 10 parts of ethyl 4-[(2,6-dimethylphenyl)-amino]-1-piperidinecarboxylate and 135 parts of hydrobromic acid solution 48% is stirred at a temperature of between 80 and 110°C until the evolution of gaseous carbon dioxide ends (after approx. 1 hour). The red colored reaction mixture is evaporated in vacuo. The residue is taken up in 56 parts of methylbenzene and the latter is evaporated again. The evaporation is repeated in a mixture of 24 parts of 2-propanone and 40 parts of methylbenzene. The resulting semi-solid residue is triturated in 80 parts of hot 2-propanone and upon cooling the solid product precipitates. It is filtered off and washed respectively with small amounts of absolute ethanol and 2-propanone and dried which gives 13 parts of N-(2,6-dimethylphenyl)-4-piperi-
Eksempel IX Example IX
En blanding av 7 deler etyl-4-(2-pyrimidinylamino)-1-piperidinkarboksylat og 120 deler hydrobromsyreoppløsning A mixture of 7 parts ethyl 4-(2-pyrimidinylamino)-1-piperidine carboxylate and 120 parts hydrobromic acid solution
48% omrøres og kokes under tilbakeløp i 2 timer. Reaksjonsblandingen fordampes og resten tas opp i vann. Det hele gjøres alkalisk med fortynnet natriumhydroksydoppløsning under av-kjøling i et isbad. Produktet ekstraheres med diklormetan. Ekstraktet tørkes, filtreres og fordampes. Den faste rest om-røres med 2,2'-oksybispropan. Produktet frafiltreres og omdannes til hydrokloridsaltet i 2-propanol. Saltet fra filtreres og krystalliseres fra etanol noe som gir 2 deler N-(4-piperidi-nyl)-2-pyrimidinamindihydroklorid-hemihydrat med smeltepunkt 268,5°C. 48% is stirred and boiled under reflux for 2 hours. The reaction mixture is evaporated and the residue taken up in water. The whole is made alkaline with dilute sodium hydroxide solution while cooling in an ice bath. The product is extracted with dichloromethane. The extract is dried, filtered and evaporated. The solid residue is stirred with 2,2'-oxybispropane. The product is filtered off and converted to the hydrochloride salt in 2-propanol. The salt from is filtered and crystallized from ethanol, which gives 2 parts of N-(4-piperidinyl)-2-pyrimidinamine dihydrochloride hemihydrate with a melting point of 268.5°C.
Eksempel X Example X
En blanding av 32,5 deler metyl-4-(fenylamino)-1-(fenylmetyl)-4-piperidinkarboksylat og 200 deler metanol hydrogeneres ved normalt trykk og ved værelsestemperatur med 5 deler palladium-på-kullkatalysator 10%. Etterat den beregnede mengde hydrogen er tatt opp, frafiltreres katalysatoren og filtratet fordampes. Den oljeaktige rest størkner ved skraping i 2,2'-oksybispropan. Produktet frafiltreres og tørkes i vakumm noe som gir 20 deler (85%) metyl-4-(fenylamino)-4-piperidinkarboksylat med smeltepunkt 139,1°C. A mixture of 32.5 parts of methyl 4-(phenylamino)-1-(phenylmethyl)-4-piperidine carboxylate and 200 parts of methanol is hydrogenated at normal pressure and at room temperature with 5 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen has been taken up, the catalyst is filtered off and the filtrate is evaporated. The oily residue solidifies by scraping in 2,2'-oxybispropane. The product is filtered off and dried under vacuum, which gives 20 parts (85%) of methyl 4-(phenylamino)-4-piperidine carboxylate with a melting point of 139.1°C.
Eksempel XI Example XI
Til en omrørt oppløsning av 58 deler etyl-4-[(4-klorfenyl)amino]-1-piperidinkarboksylat i 240 deler benzen tilsettes dråpevis en oppløsning av 46,2 deler benzenacetylklorid i 80 deler benzen ved en temperatur mellom 40 og 70°C. Etterat tilsatsen er avsluttet, omrøres blandingen og kokes under tilbakeløp i 6 timer og 15 min. Reaksjonsblandingen av-kjøles og filtreres. Filtratet vaskes med vann, natriumhydrogen-karbonatoppløsning og vann hvoretter det tørkes og fordampes i vakuum. Resten krystalliseres fra 1,1'-oksybisetan noe som gir 47 deler etyl-4-[N-(4-klorfenyl)-N-(fenylacetyl)amino]-1-piperidinkarboksylat med smeltepunkt 108°C. To a stirred solution of 58 parts of ethyl 4-[(4-chlorophenyl)amino]-1-piperidinecarboxylate in 240 parts of benzene is added dropwise a solution of 46.2 parts of benzene acetyl chloride in 80 parts of benzene at a temperature between 40 and 70°C . After the addition has ended, the mixture is stirred and boiled under reflux for 6 hours and 15 minutes. The reaction mixture is cooled and filtered. The filtrate is washed with water, sodium hydrogen carbonate solution and water, after which it is dried and evaporated in a vacuum. The residue is crystallized from 1,1'-oxybisethane, which gives 47 parts of ethyl 4-[N-(4-chlorophenyl)-N-(phenylacetyl)amino]-1-piperidinecarboxylate with a melting point of 108°C.
Eksempel XII Example XII
Under anvendelse av fremgangsmåten fra eks. XI Using the method from ex. XI
og ved å bruke ekvivalente mengder henholdsvis av et passende and by using equivalent amounts respectively of an appropriate
etyl-4-arylamino-l-piperidinkarboksylat og et passende arylacetylklorid istedenfor etyl-4-[(4-klorfenyl)amino]-1-piperidinkarboksylat og benzenacetylklorid fremstilles følgende forbindelser: ethyl 4-arylamino-1-piperidine carboxylate and a suitable aryl acetyl chloride instead of ethyl 4-[(4-chlorophenyl)amino]-1-piperidine carboxylate and benzene acetyl chloride, the following compounds are prepared:
Eksempel XIII Example XIII
Til en omrørt oppløsning av 8 deler etyl-4-[(2,6-dimetylfenyl)amino]-1-piperidinkarboksylat i 4 deler pyridin og 80 deler benzen tilsettes dråpevis 7,7 deler benzenacetylklorid i 40 deler benzen. Etter at tilsatsen er avsluttet, oppvarmes det hele til tilbakeløp og omrøres ved tilbakeløpstemperaturen i 3 timer og 45 min. Reaksjonsblandingen avkjøles og filtreres. Benzenfasen vaskes med vann og deretter med natriumhydrogen-karbonatoppløsning og med vann. Etter fordampning tilveiebringes en oljeaktig rest som stivner ved triturering ved 1,1'-oksybisetan og gir 5 deler etyl-4-[N-(2,6-dimetylfenyl)-N-(fenylacetyl)amino]-1-piperidinkarboksylat med smeltepunkt 106°C. To a stirred solution of 8 parts of ethyl 4-[(2,6-dimethylphenyl)amino]-1-piperidinecarboxylate in 4 parts of pyridine and 80 parts of benzene, 7.7 parts of benzene acetyl chloride in 40 parts of benzene are added dropwise. After the addition has ended, the whole is heated to reflux and stirred at the reflux temperature for 3 hours and 45 minutes. The reaction mixture is cooled and filtered. The benzene phase is washed with water and then with sodium hydrogen carbonate solution and with water. After evaporation, an oily residue is provided which solidifies on trituration with 1,1'-oxybisethane and gives 5 parts of ethyl 4-[N-(2,6-dimethylphenyl)-N-(phenylacetyl)amino]-1-piperidinecarboxylate with melting point 106 °C.
Eksempel XIV Example XIV
Til en omrørt oppløsning av 15 deler etyl-4-[(4-klorfenylamino]-l-piperidinkarboksylat, 5,4 deler N,N-dietyl-etanamin og 160 deler benzen tilsettes dråpevis 11,07 deler 4-metoksybenzenacetylklorid ved en temperatur på mellom 3 2 og 40°C. Etter at tilsatsen er avsluttet, omrøres det hele og kokes under tilbakeløp i 3 timer. Reaksjonsblandingen avkjøles og filtreres. Filtratet vaskes med vann, natriumhydrogenkarbon-atoppløsning og vann, tørkes, filtreres og fordampes i vakuum. Den oljeaktige rest krystalliseres fra en blanding av 56 deler 1,1'-oksybisetan og 40 deler heksan. Det urensede, faste produkt frafiltreres og rekrystalliseres fra en blanding av benzen og 1,1<1->oksybisetan noe som gir 3 deler etyl-4-{N-(4-klorfenyl)-N-[(4-metoksyfenyl)acetyl]amino}-l-piperidinkarboksylat med smeltepunkt 137°C. To a stirred solution of 15 parts of ethyl 4-[(4-chlorophenylamino]-1-piperidinecarboxylate, 5.4 parts of N,N-diethylethanamine and 160 parts of benzene, 11.07 parts of 4-methoxybenzene acetyl chloride are added dropwise at a temperature of between 32 and 40°C. After the addition is complete, the whole is stirred and refluxed for 3 hours. The reaction mixture is cooled and filtered. The filtrate is washed with water, sodium bicarbonate solution and water, dried, filtered and evaporated in vacuo. The oily residue is crystallized from a mixture of 56 parts of 1,1'-oxybisethane and 40 parts of hexane.The crude solid product is filtered off and recrystallized from a mixture of benzene and 1,1<1->oxybisethane to give 3 parts of ethyl-4 -{N-(4-chlorophenyl)-N-[(4-methoxyphenyl)acetyl]amino}-1-piperidine carboxylate with melting point 137°C.
Eksempel XV Example XV
En blanding av 20 deler etyl-4-[N-(2-klorfenyl)-N-(fenylacetyl)amino]-1-piperidinkarboksylat og 300 deler hydro-bromsyreoppløsning 48% omrøres og kokes under tilbakeløp i 1 time og 10 min. Hydrobromsyreoppløsningen på 48% fjernes i vakuum og til resten tilsettes vann og deretter natriumhydrok-sydoppløsning. Den frie base ekstraheres med triklormetan. Tri-klormetanen tørkes og fordampes. Den faste rest vaskes med 1,1'-oksybisetan og tørkes noe som gir 10,6 deler N-(2-klorfenyl)-N- A mixture of 20 parts of ethyl 4-[N-(2-chlorophenyl)-N-(phenylacetyl)amino]-1-piperidine carboxylate and 300 parts of hydrobromic acid solution 48% is stirred and refluxed for 1 hour and 10 minutes. The hydrobromic acid solution of 48% is removed under vacuum and water and then sodium hydroxide solution are added to the remainder. The free base is extracted with trichloromethane. The trichloromethane is dried and evaporated. The solid residue is washed with 1,1'-oxybisethane and dried, which gives 10.6 parts of N-(2-chlorophenyl)-N-
(4-piperidinyl)benzenacetamid med smeltepunkt 135,5°C. (4-piperidinyl)benzeneacetamide with melting point 135.5°C.
Eksempel XVI Example XVI
Ved å følge den fremgangsmåte som er gjengitt i eks. XV og ved å bruke den ekvivalente mengde av et passende etyl-4-[N-aryl-N-(arylacetyl)amino]-1-piperidinkarboksylat istedenfor etyl-4-[N-(2-klorfenyl)-N-(fenylacetyl)amino]-l-piperidinkarboksylat som anvendes i eks. XV fremstilles følg-ende forbindelser: By following the procedure that is reproduced in ex. XV and using the equivalent amount of an appropriate ethyl 4-[N-aryl-N-(arylacetyl)amino]-1-piperidinecarboxylate in place of ethyl 4-[N-(2-chlorophenyl)-N-(phenylacetyl) amino]-1-piperidine carboxylate which is used in ex. XV the following compounds are produced:
Eksempel XVII Example XVII
En blanding av 5 deler etyl-4-[N-(2,6-dimetvlfenvl)-N-(fenylacetyl)amino]-1-piperidinkarboksylat i 60 deler hydro-bromsyreoppløsning 48% oppvarmes inntil utviklingen av karbondioksyd er avsluttet. Oppvarmingen fortsetter i 15 min. til en temperatur mellom 80 og 120°C. Reaksjonsblandingen fordampes. Den faste rest vaskes med metylbenzen over 2-propanon og tørkes noe som gir 4,1 deler N-(2,6-dimetylfenyl)-N-(4-piperidinyl)-benzenacetamidhydrobromid med smeltepunkt 251,5°C. A mixture of 5 parts of ethyl 4-[N-(2,6-dimethylphenyl)-N-(phenylacetyl)amino]-1-piperidinecarboxylate in 60 parts of hydrobromic acid solution 48% is heated until the evolution of carbon dioxide has ceased. The heating continues for 15 min. to a temperature between 80 and 120°C. The reaction mixture is evaporated. The solid residue is washed with methylbenzene over 2-propanone and dried, which gives 4.1 parts of N-(2,6-dimethylphenyl)-N-(4-piperidinyl)-benzeneacetamide hydrobromide with a melting point of 251.5°C.
Eksempel XVIII Example XVIII
En blanding av 10 deler etyl-4-[N-(4-klorfenyl)-N-(fenylacetyl)amino]-1-piperidinkarboksylat og 125 deler is-eddiksyre som på forhånd er mettet med gassformet hydrogen-bromid oppvarmes i 9 timer og 4 5 min. ved 6 2°C under omrøring. Reaksjonsblandingen avkjøles og iseddiksyren fordampes i vakuum. Den halvfaste rest tas opp i 150 deler vann, gjøres alkalisk A mixture of 10 parts of ethyl 4-[N-(4-chlorophenyl)-N-(phenylacetyl)amino]-1-piperidine carboxylate and 125 parts of glacial acetic acid previously saturated with gaseous hydrogen bromide is heated for 9 hours and 4 5 min. at 6 2°C with stirring. The reaction mixture is cooled and the glacial acetic acid is evaporated in vacuo. The semi-solid residue is taken up in 150 parts water, made alkaline
med konsentrert natriumhydroksydoppløsning og produktet ekstraheres med triklormetan. Ekstraktet tørkes over natriumsulfat og fordampes. Den oljeaktige rest tritureres i 56 deler 1,1'-oksybisetan og den faste, urensede frie base frafiltreres. with concentrated sodium hydroxide solution and the product is extracted with trichloromethane. The extract is dried over sodium sulfate and evaporated. The oily residue is triturated in 56 parts of 1,1'-oxybisethane and the solid, unpurified free base is filtered off.
Den omdannes til hydrokloridsaltet på vanlig måte i 1,1'-oksybisetan og 2-propanon noe som gir 4 deler N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamidhydroklorid med smeltepunkt 206,5°C. It is converted to the hydrochloride salt in the usual way in 1,1'-oxybisethane and 2-propanone which gives 4 parts of N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide hydrochloride with a melting point of 206.5°C.
Eksempel xix Example xix
Ved å følge fremgangsmåten fra eks. XVIII oa med å bruke en ekvivalent mengde av et passende etyl-4-[N-aryl-N-(aryl-acetyl)amino]-1-piperidinkarboksylat som utgangsmateriale fremstilles følgende forbindelser: N-(2,6-dimetylfenyl)-N-(4-piperidinyl)-2-tiofenacetamid; smp. 128°C; N-(4-klorfenyl)-N-(4-piperidinyl)-2-tiofenacetamidhydroklorid; smp. 201,5°C; By following the procedure from e.g. XVIII oa using an equivalent amount of a suitable ethyl 4-[N-aryl-N-(aryl-acetyl)amino]-1-piperidine carboxylate as starting material, the following compounds are prepared: N-(2,6-dimethylphenyl)-N -(4-piperidinyl)-2-thiophenacetamide; m.p. 128°C; N-(4-chlorophenyl)-N-(4-piperidinyl)-2-thiophenacetamide hydrochloride; m.p. 201.5°C;
4-klor-N-(4-klorfenyl)-N-(4-piperidinyl)4-benzenacetamidhydro-klorid; smp. 222°C; og 4-chloro-N-(4-chlorophenyl)-N-(4-piperidinyl)4-benzeneacetamide hydrochloride; m.p. 222°C; and
N-(4-klorfenyl)-4-metyl-N-(4-piperidinyl)benzenacetamid; smp. 121°C. N-(4-chlorophenyl)-4-methyl-N-(4-piperidinyl)benzeneacetamide; m.p. 121°C.
Eksempel XX. Example XX.
Til en blanding som kokes under tilbakeløp og om-røres og som består av 48 deler l-(1-metyletyl)-4-piperidinon, To a refluxed and stirred mixture consisting of 48 parts of 1-(1-methylethyl)-4-piperidinone,
1 del 4-metylbenzensulfonsyre og 540 deler metylbenzen tilset- 1 part 4-methylbenzenesulfonic acid and 540 parts methylbenzene add-
tes dråpevis en oppløsning av 30 deler benzenamin i 90 deler metylbenzen. Etterat tilsatsen er avsluttet, omrøres bland- dropwise a solution of 30 parts benzenamine in 90 parts methylbenzene. After the addition has ended, stir the mix-
ingen og kokes under tilbakeløp i 3 timer med vannseparator. Reaksjonsblandingen fordampes, noe som gir 72 deler N-[l-(l-metyletyl)-4-piperidinyliden]benzenamin som en rest. none and boil under reflux for 3 hours with a water separator. The reaction mixture is evaporated, giving 72 parts of N-[1-(1-methylethyl)-4-piperidinylidene]benzenamine as a residue.
Til en omrørt og oppvarmet (30-40°C) oppløsning To a stirred and heated (30-40°C) solution
av 72 deler N-[1-(1-metyletyl)-4-piperidinyliden]benzenamin i 480 deler metanol tilsettes porsjonsvis 20 deler natriumborhydrid. Etter at tilsatsen er avsluttet, fortsettes omrøringen over natten ved værelsestemperatur. Reaksjonsblandingen fordampes og resten oppløses i vann. Oppløsningen ekstraheres med 4-metyl-2-pentanon. Ekstraktet vaskes med vann og sur-gjøres med fortynnet saltsyreoppløsning. Den vandige sure fase gjøres alkalisk med fortynnet natriumhydroksydoppløsning til pH 9 og produktet ekstraheres med 4-metyl-2-pentanon. Ekstraktet vaskes med vann, tørkes, filtreres og fordampes. Resten destilleres (kokepunkt 135-140°C ved 0,2 mm trykk) og destillatet krystalliseres fra petroleter noe som gir 21 deler 1-(1-metyletyl)-N-fenyl-4-piperidinamin med smeltepunkt 69,3°C. of 72 parts of N-[1-(1-methylethyl)-4-piperidinylidene]benzenamine in 480 parts of methanol, 20 parts of sodium borohydride are added in portions. After the addition has ended, stirring is continued overnight at room temperature. The reaction mixture is evaporated and the residue is dissolved in water. The solution is extracted with 4-methyl-2-pentanone. The extract is washed with water and acidified with dilute hydrochloric acid solution. The aqueous acid phase is made alkaline with dilute sodium hydroxide solution to pH 9 and the product is extracted with 4-methyl-2-pentanone. The extract is washed with water, dried, filtered and evaporated. The residue is distilled (boiling point 135-140°C at 0.2 mm pressure) and the distillate is crystallized from petroleum ether, which gives 21 parts of 1-(1-methylethyl)-N-phenyl-4-piperidinamine with a melting point of 69.3°C.
Eksempel XXI Example XXI
Til en varm (40°C) oppløsning av 12 deler kaliumhydroksyd i 240 deler 2-propanol tilsettes på en gang 21 deler etyl-4-{N-(4-klorfenyl)-N-[(4-metoksyfenyl)acetyl]amino}-l-piperidinkarboksylat og blandingen omrøres og kokes under til-bakeløp i 21 timer. Reaksjonsblandingen avkjøles, filtreres og filtratet fordampes. Resten tas opp i vann og den vandige oppløsning gjøres sur med fortynnet saltsyreoppløsning. Den sure oppløsningen vaskes med 1,1'-oksybisetan, gjøres alkalisk med natriumhydroksyd og den frie base ekstraheres med metylbenzen. Den sistnevnte tørkes, filtreres og fordampes. Resten oppløses To a warm (40°C) solution of 12 parts of potassium hydroxide in 240 parts of 2-propanol, 21 parts of ethyl-4-{N-(4-chlorophenyl)-N-[(4-methoxyphenyl)acetyl]amino} are added at once -1-piperidine carboxylate and the mixture is stirred and refluxed for 21 hours. The reaction mixture is cooled, filtered and the filtrate is evaporated. The residue is taken up in water and the aqueous solution is made acidic with dilute hydrochloric acid solution. The acidic solution is washed with 1,1'-oxybisethane, made alkaline with sodium hydroxide and the free base is extracted with methylbenzene. The latter is dried, filtered and evaporated. The rest dissolves
i 1,1'-oksybisetan og etter krystallisasjon tilveiebringes 10 deler N-(4-klorfenyl)-4-metoksy-N-(4-piperidinyl)benzenacetamid med smeltepunkt 129,5°C. in 1,1'-oxybisethane and after crystallization, 10 parts of N-(4-chlorophenyl)-4-methoxy-N-(4-piperidinyl)benzeneacetamide with melting point 129.5°C are obtained.
Eksempel XXII Example XXII
Til en omrørt og varm (40°C) oppløsning av 12 deler kaliumhydroksyd i 200 deler 2-propanol tilsettes på en gang 21 deler etyl-4-{N-(4-klorfenyl)-N-[(3-metoksyfenyl)acetyl]-amino}-1-piperidinkarboksylat og blandingen omrøres og kokes under til-bakeløp i 17 timer. Reaksjonsblandingen avkjøles, filtreres og fordampes. Den halvfaste rest surgjøres med fortynnet saltsyre-oppløsning, vaskes med 1,1'-oksybisetan og den vandige, sure fase gjøres alkalisk med natriumhydroksydoppløsning. Den frie base ekstraheres med triklormetan. Ekstraktet tørkes og fordampes. Resten krystalliseres fra en blanding av 1,1'-oksybisetan og heksan noe som gir 7,8 deler N-(4-klorfenyl)-3-metoksy-N-(4-piperidinyl)benzenacetamid med smeltepunkt 85,7°C. To a stirred and warm (40°C) solution of 12 parts of potassium hydroxide in 200 parts of 2-propanol, 21 parts of ethyl-4-{N-(4-chlorophenyl)-N-[(3-methoxyphenyl)acetyl] are added at once -amino}-1-piperidine carboxylate and the mixture is stirred and refluxed for 17 hours. The reaction mixture is cooled, filtered and evaporated. The semi-solid residue is acidified with dilute hydrochloric acid solution, washed with 1,1'-oxybisethane and the aqueous, acidic phase is made alkaline with sodium hydroxide solution. The free base is extracted with trichloromethane. The extract is dried and evaporated. The residue is crystallized from a mixture of 1,1'-oxybisethane and hexane which gives 7.8 parts of N-(4-chlorophenyl)-3-methoxy-N-(4-piperidinyl)benzeneacetamide with a melting point of 85.7°C.
Eksempel XXIII Example XXIII
En blanding av 52 deler 2-brompropan, 19 deler N-(4-piperidinyl)-3-pyridinamin, 33,3 deler natriumkarbonat, 3 deler kaliumjodid og 720 deler 4-metyl-2-pentanon omrøres og kokes under tilbakeløp i 24 timer. Reaksjonsblandingen avkjøles og filtreres. Filtratet fordampes. Resten renses ved kolonnekromatografi over silikagel under anvendelse av metanol som elueringsmiddel. De rene fraksjoner oppsamles og elueringsmidlet fordampes. Resten krystalliseres fra 2,2<1->oksybispropan noe som gir 1,5 deler N-[1-(1-metyletyl)-4-piperidinyl]-3-pyridinamin med smeltepunkt 100,7%. A mixture of 52 parts of 2-bromopropane, 19 parts of N-(4-piperidinyl)-3-pyridinamine, 33.3 parts of sodium carbonate, 3 parts of potassium iodide and 720 parts of 4-methyl-2-pentanone is stirred and refluxed for 24 hours . The reaction mixture is cooled and filtered. The filtrate is evaporated. The residue is purified by column chromatography over silica gel using methanol as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 2,2<1->oxybispropane which gives 1.5 parts of N-[1-(1-methylethyl)-4-piperidinyl]-3-pyridinamine with a melting point of 100.7%.
Eksempel XXIV Example XXIV
Under anvendelsen av fremgangsmåten fra eksempel 25 og ved å bruke ekvivalente mengder av henholdsvis et passende bromid og av et passende 4-(acetylamino)-4-X-piperidin som utgangsmaterialer og ved å utføre reaksjonen i det angitte opp-løsningsmiddel tilveiebringes følgende forbindelser i form av sine frie baser eller i form av hydrokloridsaltet etter behandling med saltsyre: Applying the procedure of Example 25 and using equivalent amounts of a suitable bromide and of a suitable 4-(acetylamino)-4-X-piperidine respectively as starting materials and carrying out the reaction in the indicated solvent, the following compounds are provided in form of its free bases or in the form of the hydrochloride salt after treatment with hydrochloric acid:
Eksempel XXV Example XXV
Til en omrørt blanding av 15 deler N-(4-klorfenyl)-4-piperidinamin, 12 deler N,N-dietyletanamin i 130 deler benzen tilsettes dråpevis til en oppløsning av 10,3 deler 3-brom-l-popen i 70 deler benzen. Etterat tilsatsen er avsluttet, om-røres det hele først i 20 timer og 30 min. ved værelsestemperatur og deretter i 40 min. ved tilbakeløpstemperatur. Reaksjonsblandingen avkjøles, filtreres og filtratet fordampes. Resten tas opp i 1,1'-oksybisetan og behandles med aktivt kull. Den sistnevnte frafiltreres og 1,1<1->oksybisetan fordampes igjen noe som gir 2,9 deler N-(4-klorfenyl)-1-(2-propenyl)-4-piperidinamin med smeltepunkt 9 0°C. To a stirred mixture of 15 parts of N-(4-chlorophenyl)-4-piperidinamine, 12 parts of N,N-diethylethanamine in 130 parts of benzene is added dropwise to a solution of 10.3 parts of 3-bromo-l-popene in 70 parts benzene. After the addition has ended, the whole thing is first stirred for 20 hours and 30 minutes. at room temperature and then for 40 min. at reflux temperature. The reaction mixture is cooled, filtered and the filtrate is evaporated. The remainder is taken up in 1,1'-oxybisethane and treated with activated charcoal. The latter is filtered off and 1,1<1->oxybisethane is evaporated again, which gives 2.9 parts of N-(4-chlorophenyl)-1-(2-propenyl)-4-piperidineamine with a melting point of 90°C.
Eksempel XXVI Example XXVI
Til en varm (ca. 40°C) og omrørt blanding av 5 deler N-(2,6-dimetylfenyl)-4-piperidinamin, 5 deler natriumkarbonat, noen krystaller kaliumjodid i 120 deler benzen tilsettes dråpevis til en oppløsning av 5,1 deler 1-jodpropan i 80 deler benzen. Etter at tilsatsen er avsluttet, fortsettes omrøringen i 40 timer ved tilbakeløpstemperaturen. Reaksjonsblandingen avkjøles og 50 deler vann tilsettes. Det organiske lag fraskilles, tørkes og fordampes i vakuum. Den oljeaktige rest destilleres, noe som gir 10,2 deler N-(2,6-dimetylfenyl)-1-propyl-4-piperidinamin med kokepunkt 135°C ved 0,2 mm trykk. To a warm (approx. 40°C) and stirred mixture of 5 parts N-(2,6-dimethylphenyl)-4-piperidinamine, 5 parts sodium carbonate, some crystals of potassium iodide in 120 parts benzene are added dropwise to a solution of 5.1 parts of 1-iodopropane in 80 parts of benzene. After the addition has ended, stirring is continued for 40 hours at the reflux temperature. The reaction mixture is cooled and 50 parts of water are added. The organic layer is separated, dried and evaporated in vacuo. The oily residue is distilled, which gives 10.2 parts of N-(2,6-dimethylphenyl)-1-propyl-4-piperidinamine with boiling point 135°C at 0.2 mm pressure.
Eksempel XXVII Example XXVII
Til 0,5 deler av en oppløsning av 2 deler tio- To 0.5 parts of a solution of 2 parts thio-
fen i 40 deler etanol tilsettes 2 deler cyklopentanon, 5,5 fen in 40 parts ethanol, 2 parts cyclopentanone are added, 5.5
deler N-(4-piperidinyl)-2-pyrimidinamin og 120 deler metanol. Blandingen hydrogeneres ved normalt trykk og ved værelsestemperatur med 2 deler palladium-på-kull 10%. Etter at den beregnede mengde hydrogen er tatt opp, filtreres katalysatoren fra og filtratet fordampes. Resten tas opp i 4-metyl-2-pentanon og en liten mengde triklormetan. Blandingen vaskes to ganger med fortynnet natriumhydroksydoppløsning, tørkes, filtreres og fordampes. Resten krystalliseres fra 2,2'-oksybispropan. Produktet filtreres fra og tørkes noe som gir 2,3 deler N-(l-cyklopentyl-4-piperidinyl)-2-pyrimidinamin med smeltepunkt 118°C. parts N-(4-piperidinyl)-2-pyrimidinamine and 120 parts methanol. The mixture is hydrogenated at normal pressure and at room temperature with 2 parts palladium-on-charcoal 10%. After the calculated amount of hydrogen has been taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is taken up in 4-methyl-2-pentanone and a small amount of trichloromethane. The mixture is washed twice with dilute sodium hydroxide solution, dried, filtered and evaporated. The residue is crystallized from 2,2'-oxybispropane. The product is filtered off and dried, which gives 2.3 parts of N-(1-cyclopentyl-4-piperidinyl)-2-pyrimidinamine with a melting point of 118°C.
Eksempel XXVIII Example XXVIII
Til 0,5 deler av en oppløsning av 2 deler tiofen To 0.5 parts of a solution of 2 parts thiophene
i 40 deler etanol tilsettes 4 deler 2-propanon, 4,5 deler N-(4-piperidinyl)-2-pyrimidinamin og 120 deler metanol. Blandingen hydrogeneres ved normalt trykk og ved værelsestemperatur med 2 deler palladium-på-kullkatalysator 10%. Etterat den beregnede mengde hydrogen er tatt opp, frafiltreres katalysatoren og filtratet fordampes. Resten oppløses i triklormetan. Oppløsningen vaskes med fortynnet natriumhydroksydoppløsning og med vann, tørkes, filtreres og fordampes noe som gir 3 deler N-[l-(l-metyletyl)-4-piperidinyl]-2-pyrimidinamin som en rest. in 40 parts of ethanol, 4 parts of 2-propanone, 4.5 parts of N-(4-piperidinyl)-2-pyrimidinamine and 120 parts of methanol are added. The mixture is hydrogenated at normal pressure and at room temperature with 2 parts palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen has been taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is dissolved in trichloromethane. The solution is washed with dilute sodium hydroxide solution and with water, dried, filtered and evaporated to give 3 parts of N-[1-(1-methylethyl)-4-piperidinyl]-2-pyrimidinamine as a residue.
Eksempel XXIX Example XXIX
Til en suspensjon som omrøres og kokes under til-bakeløp og som består av 2 deler litiumaluminiumhydrid i 120 deler 1,1<1->oksybisetan tilsettes dråpevis en oppløsning av 13 deler etyl-4-[N-(2,6-dimetylfenyl)amino]- 1-piperidinkarboksylat i 40 deler 1,1'-oksybisetan. Etterat tilsatsen er avsluttet, fortsettes tilbakeløpskokingen og omrøringen i 20 timer. Reaksjonsblandingen avkjøles til 5°C og 7 deler vann tilsettes bunnfallet som danner seg, frafiltreres, vaskes på filteret med 1,1<1->oksybisetan og filtratet fordampes. Den oljeaktige rest destilleres, noe som gir 5,8 deler N-(2,6-dimetylfenyl)-1-metyl-4-piperidinamin med kokepunkt 90-93°C ved 0,003 mm trykk. Ved henstand størkner destillatet og gir fast N-(2,6-dimetylfenyl)-l-metyl-4-piperidinamin med et smeltepunkt på 45°C. A solution of 13 parts ethyl-4-[N-(2,6-dimethylphenyl) amino]-1-piperidinecarboxylate in 40 parts of 1,1'-oxybisethane. After the addition has ended, refluxing and stirring are continued for 20 hours. The reaction mixture is cooled to 5°C and 7 parts of water are added, the precipitate which forms is filtered off, washed on the filter with 1,1<1->oxybisethane and the filtrate is evaporated. The oily residue is distilled, which gives 5.8 parts of N-(2,6-dimethylphenyl)-1-methyl-4-piperidinamine with a boiling point of 90-93°C at 0.003 mm pressure. On standing, the distillate solidifies and gives solid N-(2,6-dimethylphenyl)-1-methyl-4-piperidinamine with a melting point of 45°C.
De følgende eksempler beskriver fremstilling av sluttprodukter. The following examples describe the production of final products.
Eksempel 1 Example 1
Til en omrørt suspensjon av 5 deler N-(4-klor-fenyl)-N-(4-piperidinyl)benzenacetamid, 5 deler natriumkarbonat og noen få krystaller kaliumjodid i 200 deler butanol tilsettes dråpevis 4 deler 2-brompropan ved værelsestemperatur. Etterat tilsatsen er avsluttet, omrøres blandingen og kokes under til-bakeløp i 20 timer. Deretter tilsettes en annen porsjon 4 deler 2-brompropanon og omrøringen og tilbakeløpskokingen fortsetter i ytterligere 19 timer. Reaksjonsblandingen avkjøles, filtreres og filtratet fordampes. Fra den oljeaktige, frie base fremstilles hydrokloridsaltet på vanlig måte i en 1,1'-oksybisetan og 2-propanon. Det utfelte, faste salt frafiltreres og krystalliseres fra en blanding av 2-propanon og 2-propanol, noe som gir 2 deler N-(4-klorfenyl)-N-[1-(1-metyletyl)-4-piperidinyl]benzenacetamidhydroklorid med smeltepunkt 26 3°C. To a stirred suspension of 5 parts of N-(4-chloro-phenyl)-N-(4-piperidinyl)benzeneacetamide, 5 parts of sodium carbonate and a few crystals of potassium iodide in 200 parts of butanol, 4 parts of 2-bromopropane are added dropwise at room temperature. After the addition has ended, the mixture is stirred and refluxed for 20 hours. Then another portion of 4 parts 2-bromopropanone is added and stirring and refluxing are continued for a further 19 hours. The reaction mixture is cooled, filtered and the filtrate is evaporated. From the oily, free base, the hydrochloride salt is prepared in the usual way in a 1,1'-oxybisethane and 2-propanone. The precipitated solid salt is filtered off and crystallized from a mixture of 2-propanone and 2-propanol, yielding 2 parts of N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]benzeneacetamide hydrochloride with melting point 26 3°C.
Eksempel 2 Example 2
Ved å følge fremgangsmåten fra eks. 1 og ved å anvende en ekvivalent mengde av et passende bromid og av et passende stort N-aryl-N-(4-piperidinyl)arylacetamid, fremstilles følgende forbindelser som hydrokloridsalter: By following the procedure from e.g. 1 and by using an equivalent amount of an appropriate bromide and of an appropriately large N-aryl-N-(4-piperidinyl)arylacetamide, the following compounds are prepared as hydrochloride salts:
Eksempel 3 Example 3
Til en omrørt og varm (40°C) blanding av 5 deler N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid, 5 deler natriumkarbonat, noen krystaller kaliumjodid og 200 deler n-butanol tilsettes 3,75 deler bromcyklopentan og blandingen omrøres og kokes under tilbakeløp i 21 timer og 30 min. Deretter tilsettes en annen porsjon av 5 deler bromcyklopentan og omrøringen og tilbakeløpskokingen fortsettes i ytterligere 30 timer. Reaksjonsblandingen avkjøles, filtreres og filtratet fordampes. To a stirred and warm (40°C) mixture of 5 parts of N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide, 5 parts of sodium carbonate, some crystals of potassium iodide and 200 parts of n-butanol, 3.75 parts of bromocyclopentane are added and the mixture is stirred and refluxed for 21 hours and 30 minutes. Another portion of 5 parts bromocyclopentane is then added and the stirring and refluxing are continued for a further 30 hours. The reaction mixture is cooled, filtered and the filtrate is evaporated.
Den oljeaktige rest størkner ved triturering i 1,1'-oksybisetan. Det faste produkt frafiltreres og krystalliseres fra 1,1'-oksybisetan noe som gir 1,1 deler N-(4-klorfenyl)-N-(1-cyklo-pentyl-4-piperidinyl)benzenacetamid med smeltepunkt 139,5°C. The oily residue solidifies by trituration in 1,1'-oxybisethane. The solid product is filtered off and crystallized from 1,1'-oxybisethane, which gives 1.1 parts of N-(4-chlorophenyl)-N-(1-cyclopentyl-4-piperidinyl)benzeneacetamide with a melting point of 139.5°C.
Eksempel 4 Example 4
Ved å følge fremgangsmåten fra eks. 3 og ved å bruke ekvivalente mengder av henholdsvis et passende bromid og av en passende N-aryl-N-(4-piperidinyl)arylacetamid som utgangsmaterialer, fremstilles følgende forbindelser: By following the procedure from e.g. 3 and using equivalent amounts of a suitable bromide and of a suitable N-aryl-N-(4-piperidinyl)arylacetamide respectively as starting materials, the following compounds are prepared:
Eksempel 5 Example 5
Til en blanding som omrøres og kokes under tilbakeløp og som består av 5 deler N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid, 5 deler natriumhydrogenkarbonat og 200 deler benzen tilsettes porsjonsvis 6,7 deler (brommetyl)cyklopropan og omrøringen og tilbakeløpskokingen fortsetter i 23 timer. Reaksjonsblandingen avkjøles og filtreres. Filtratet fordampes. Den halvfaste rest oppløses i en blanding av benzen og 1,1'-oksybisetan. De utfelte urenheter frafiltreres og filtratet fordampes igjen. Fra den oljeaktige, frie base fremstilles hydrokloridsaltet på vanlig måte og gir etter krystallisasjon av det urensede salt fra en blanding av triklormetan og 1,1'-oksybisetan 1,5 deler N-(4-klorfenyl)-N-[1-(cyklopropylmetyl)-4-piperidinyl]benzenacetamidhydroklorid med smeltepunkt 224°C. To a mixture which is stirred and refluxed and which consists of 5 parts N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide, 5 parts sodium bicarbonate and 200 parts benzene, 6.7 parts (bromomethyl)cyclopropane and the stirring and reflux continue for 23 hours. The reaction mixture is cooled and filtered. The filtrate is evaporated. The semi-solid residue is dissolved in a mixture of benzene and 1,1'-oxybisethane. The precipitated impurities are filtered off and the filtrate is evaporated again. From the oily, free base, the hydrochloride salt is prepared in the usual way and after crystallization of the impure salt from a mixture of trichloromethane and 1,1'-oxybisethane yields 1.5 parts of N-(4-chlorophenyl)-N-[1-(cyclopropylmethyl) )-4-piperidinyl]benzeneacetamide hydrochloride with a melting point of 224°C.
Eksempel 6 Example 6
Til en omrørt oppløsning av 5 deler N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid, 3,8 deler N,N-dietyletanamin i 200 deler benzen tilsettes porsjonsvis 5 deler 3-brom-l-prop-en. Etterat tilsatsen er avsluttet, oppvarmes blandingen i 21 timer til en temperatur på mellom 50 og 60°C. Reaksjonsblandingen avkjøles og filtreres. Filtratet vaskes med vann, natriumhydrogenkarbonatoppløsning og vann, tørkes over kaliumkarbonat og fordampes. Den oljeaktige rest omdannes til hydrokloridsaltet i 1,1<1->oksybisetan og 2-propanon noe som gir 4 deler N-(4-klorfenyl)-N-[1-(2-propenyl)-4-piperidinyl]benzen-acetamidhydroklorid med smeltepunkt 225,5°C. To a stirred solution of 5 parts of N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide, 3.8 parts of N,N-diethylethanamine in 200 parts of benzene, 5 parts of 3-bromo-l-prop-ene are added in portions . After the addition has ended, the mixture is heated for 21 hours to a temperature of between 50 and 60°C. The reaction mixture is cooled and filtered. The filtrate is washed with water, sodium bicarbonate solution and water, dried over potassium carbonate and evaporated. The oily residue is converted to the hydrochloride salt in 1,1<1->oxybisethane and 2-propanone which gives 4 parts of N-(4-chlorophenyl)-N-[1-(2-propenyl)-4-piperidinyl]benzeneacetamide hydrochloride with a melting point of 225.5°C.
Eksempel 1 Example 1
Ved å følge fremgangsmåten fra eks. 6 og ved å anvende en ekvivalent mengde av et passende N-aryl-N-(4-piperi-dinyl) -arylacetamid istedenforn N-(4-klorfenyl)-N-(4-piperidi-nyl) benzenacetamid som anvendes i dette eksempel, fremstilles følgende forbindelser: N-(2,6-dimetylfenyl-N-[1-(2-propenyl)-4-piperidinyl]-2-tiofen-acetamidhydroklorid med smeltepunkt 203,5°C og N-(2,6-dimetylfenyl)-N-[1-(2-propenyl)-4-piperidinyl]benzenacet-amidhydroklorid med smeltepunkt 214°C. By following the procedure from e.g. 6 and by using an equivalent amount of an appropriate N-aryl-N-(4-piperidinyl)-arylacetamide in place of the N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide used in this example , the following compounds are prepared: N-(2,6-dimethylphenyl-N-[1-(2-propenyl)-4-piperidinyl]-2-thiophene-acetamide hydrochloride with melting point 203.5°C and N-(2,6- dimethylphenyl)-N-[1-(2-propenyl)-4-piperidinyl]benzeneacetamide hydrochloride with melting point 214°C.
Eksempel 8 Example 8
Til en varm suspensjon av 5 deler N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid, 5 deler natriumkarbonat og noen To a hot suspension of 5 parts of N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide, 5 parts of sodium carbonate and some
få krystaller kaliumjodid i 200 deler n-butanol tilsettes 4 few crystals of potassium iodide in 200 parts of n-butanol are added 4
deler 2-klor-2-metylpropan ved en temperatur på mellom 30 og 40°C. Blandingen omrøres og kokes under tilbakeløp i 140 timer og i løpet av denne tiden tilsettes 35 deler 2-klor-2-metylpropan i porsjoner på følgende måte: etter en tilbakeløpstid på 15 splits 2-chloro-2-methylpropane at a temperature of between 30 and 40°C. The mixture is stirred and refluxed for 140 hours, during which time 35 parts of 2-chloro-2-methylpropane are added in portions as follows: after a reflux time of 15
timer tilsettes 4 deler 2-klor-2-metylpropan, etter 8 timer 10 deler og etter 16 timer 11 deler og endelig etter 47 timer 10 deler. Reaksjonsblandingen avkjøles, filtreres og filtratet fordampes. Den halvfaste rest oppløses i en blanding av metylbenzen, dimetoksyetan og 1,1'-oksybisetan. Oppløsningen frafiltreres noen urenheter og filtratet fordampes igjen. Fra den oljeaktige rest fremstilles hydrokloridsaltet på vanlig måte i 1,1'-oksybisetan noe som etter rekrystallisering av det urensede, fast salt fra 2-propanon, gir 0,9 deler N-(4-klorfenyl)-N-[1-(1,1-dimetyletyl)-4-piperidinyl]benzenacetamidhydroklorid med smeltepunkt 221°C. hours, 4 parts of 2-chloro-2-methylpropane are added, after 8 hours 10 parts and after 16 hours 11 parts and finally after 47 hours 10 parts. The reaction mixture is cooled, filtered and the filtrate is evaporated. The semi-solid residue is dissolved in a mixture of methylbenzene, dimethoxyethane and 1,1'-oxybisethane. The solution is filtered to remove any impurities and the filtrate is evaporated again. From the oily residue, the hydrochloride salt is prepared in the usual way in 1,1'-oxybisethane which, after recrystallization of the impure, solid salt from 2-propanone, yields 0.9 parts of N-(4-chlorophenyl)-N-[1-( 1,1-dimethylethyl)-4-piperidinyl]benzeneacetamide hydrochloride with melting point 221°C.
Eksempel 9 Example 9
En blanding av 4 deler jodetan, 5 deler N-(2,6-dimetylf enyl)-N-(4-piperidinyl)benzenacetamid, 5 deler natriumkarbonat, noen få krystaller kaliumjodid i 200 deler benzen om-røres og kokes under tilbakeløp i 23 timer. Reaksjonsblandingen filtreres varm og filtratet fordampes i vakuum. Den faste rest krystalliseres fra 1,1'-oksybisetan, noe som gir 2 deler A mixture of 4 parts iodoethane, 5 parts N-(2,6-dimethylphenyl)-N-(4-piperidinyl)benzeneacetamide, 5 parts sodium carbonate, a few crystals of potassium iodide in 200 parts benzene is stirred and refluxed for 23 hours. The reaction mixture is filtered hot and the filtrate is evaporated in vacuo. The solid residue is crystallized from 1,1'-oxybisethane, which gives 2 parts
N- (2, 6-dimetylf enyl) - N- (l-etvl-4-piperidinyl) benzenacetamid N-(2,6-dimethylphenyl)-N-(1-ethyl-4-piperidinyl)benzeneacetamide
med smeltepunkt 86,5oc. with melting point 86.5oc.
Eksempel 10 Example 10
Ved å følge fremgangsmåten fra eks. 9 og ved å anvende en ekvivalent mengde av et passende N-aryl-N-(4-piperidi-nyl )arylacetamid istedenfor N-(2,6-dimetylfenyl)-N-(4-piperidi-nyl) benzenacetamid ble følgende forbindelser fremstilt: 2-klor-N-(4-klorfenyl)-N-(l-etyl-4-piperidinyl)benzenacetamid-hydroklorid; smp. 234,6°C; N-(4-klorfenyl)-N- (l-etyl-4-piperidinyl)-3-metylbenzenacetamid; smp. 78,5°C; By following the procedure from e.g. 9 and using an equivalent amount of an appropriate N-aryl-N-(4-piperidinyl)arylacetamide in place of N-(2,6-dimethylphenyl)-N-(4-piperidinyl)benzeneacetamide the following compounds were prepared : 2-chloro-N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)benzeneacetamide hydrochloride; m.p. 234.6°C; N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)-3-methylbenzeneacetamide; m.p. 78.5°C;
N-(4-klorfenyl)-N-(l-etyl-4-piperidinyl)-4-metylbenzenacetamid; smp. 50°C og N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)-4-methylbenzeneacetamide; m.p. 50°C and
N-(4-klorfenyl)-N-(l-etyl-4-piperidinyl)-4-fluorbenzenacetamid; smp. 6 2,3°C. N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)-4-fluorobenzeneacetamide; m.p. 6 2.3°C.
Eksempel 11 Example 11
Til en blanding av 5 deler 4-klor-N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid, 5 deler natriumkarbonat, 0,4 deler kaliumjodid i 200 deler butanol som kokes under tilbakeløp under omrøring, tilsettes 4,7 deler 1-jodpropan og blandingen omrøres og kokes under tilbakeløp i 22 timer. Deretter tilsettes en annen porsjon av 4,5 deler 1-jodpropan og tilbakeløpskokingen og omrøringen fortsetter i 27 timer og 30 min. Reaksjonsblandingen avkjøles, filtreres og filtratet fordampes. Den halvfaste rest oppløses i metylbenzen. Oppløsningen frafiltreres noen urenheter og filtratet fordampes igjen. Resten krystalliseres fra 1,1<1->oksybisetan ved -10°C noe som gir 0,9 deler 4-klor-N-(4-klorfenyl)-N-(l-propyl-4-piperidinyl)benzenacetamid med smeltepunkt 118,6°C. To a mixture of 5 parts of 4-chloro-N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide, 5 parts of sodium carbonate, 0.4 parts of potassium iodide in 200 parts of butanol which is refluxed with stirring, is added 4, 7 parts 1-iodopropane and the mixture is stirred and refluxed for 22 hours. Another portion of 4.5 parts of 1-iodopropane is then added and refluxing and stirring are continued for 27 hours and 30 minutes. The reaction mixture is cooled, filtered and the filtrate is evaporated. The semi-solid residue is dissolved in methylbenzene. The solution is filtered to remove any impurities and the filtrate is evaporated again. The residue is crystallized from 1,1<1->oxybisethane at -10°C which gives 0.9 parts of 4-chloro-N-(4-chlorophenyl)-N-(1-propyl-4-piperidinyl)benzeneacetamide with melting point 118 .6°C.
Eksempel 12 Example 12
Til en omrørt oppløsning av 4 deler N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid og 3 deler N,N-dietyletanamin To a stirred solution of 4 parts N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide and 3 parts N,N-diethylethanamine
i 200 deler benzen tilsettes porsjonsvis 4 deler 1-jodpropan og blandingen omrøres og kokes under tilbakeløp i 47 timer. Deretter tilsettes en annen porsjon av 4 deler 1-jodpropan og omrøringen og tilbakeløpskokingen fortsetter i ytterligere 20 timer og 20 min. Reaksjonsblandingen avkjøles og filtreres. 4 parts of 1-iodopropane are added in portions to 200 parts of benzene and the mixture is stirred and refluxed for 47 hours. Another portion of 4 parts 1-iodopropane is then added and the stirring and refluxing are continued for a further 20 hours and 20 minutes. The reaction mixture is cooled and filtered.
Filtratet vaskes med vann, tørkes og fordampes i vakuum. Fra den oljeaktige, frie base, fremstilles hydrokloridsaltet på vanlig måte i 1,1'-oksybisetan. Det utfelte faste salt frafiltreres og tørkes, noe som gir 3,5 deler N-(4-klorfenyl)-N-(1-pro-pyl-4-piperidinyl)benzenacetamidhydroklorid med smeltepunkt 233,5°C. The filtrate is washed with water, dried and evaporated in vacuo. From the oily, free base, the hydrochloride salt is prepared in the usual way in 1,1'-oxybisethane. The precipitated solid salt is filtered off and dried, which gives 3.5 parts of N-(4-chlorophenyl)-N-(1-propyl-4-piperidinyl)benzeneacetamide hydrochloride with a melting point of 233.5°C.
Eksempel 13 Example 13
Ved å anvende fremgangsmåten fra eks. 12 og ved å bruke en ekvivalent mengde av henholdsvis et passende jodalkan og et passende N-aryl-N-(4-piperidinyl)arylacetamid istedenfor 1-jodpropan og N-(4-klorfenyl)-N-(4-piperidinyl)benzenacetamid ble følgende forbindelser fremstilt: N-(2,6-dimetylfenyl)-N-(l-ety1-4-piperidinyl)-2-tiofenacetamid-hydroklorid med smeltepunkt 258°C; N-(4-klorfenyl)-N-(l-etyl-4-piperidinyl)-2-tiofenacetamidhydro-klorid; smp. 220,5°C; N-(4-klorfenyl)-N-(l-etyl-4-piperidinyl)benzenacetamidhydro-klorid; smp. 215°C; By using the procedure from e.g. 12 and by using an equivalent amount of a suitable iodoalkane and a suitable N-aryl-N-(4-piperidinyl)arylacetamide respectively instead of 1-iodopropane and N-(4-chlorophenyl)-N-(4-piperidinyl)benzeneacetamide was the following compounds prepared: N-(2,6-dimethylphenyl)-N-(1-ethyl-4-piperidinyl)-2-thiophenacetamide hydrochloride of melting point 258°C; N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)-2-thiophenacetamide hydrochloride; m.p. 220.5°C; N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)benzeneacetamide hydrochloride; m.p. 215°C;
4-klor-N-(4-klorfenyl)-N-(l-etyl-4-piperidinyl)benzenacetamid-hydroklorid; smp. 224°C og 4-chloro-N-(4-chlorophenyl)-N-(1-ethyl-4-piperidinyl)benzeneacetamide hydrochloride; m.p. 224°C and
N-(4-klorfenyl)-N-(l-propyl-4-piperidinyl)2-tiofenacetamid-hydroklorid, smp. 241°C N-(4-chlorophenyl)-N-(1-propyl-4-piperidinyl)2-thiophenacetamide hydrochloride, m.p. 241°C
Eksempel 14 Example 14
En blanding av 4,5 deler N-(l-cyklopentyl-4-piperi-dinyl)-2-pyrimidinamin, 3,4 deler 3-metylbenzenacetylklorid, A mixture of 4.5 parts N-(1-cyclopentyl-4-piperidinyl)-2-pyrimidinamine, 3.4 parts 3-methylbenzeneacetyl chloride,
2 deler natriumkarbonat og 180 deler dimetylbenzen omrøres og kokes under tilbakeløp i 17 timer. Ytterligere 9 deler 3-metylbenzenacetylklorid tilsettes dråpevis. Etterat tilsatsen er avsluttet, fortsettes omrøringen i 67 timer ved tilbakeløps-temperatur. Reaksjonsblandingen avkjøles, vann tilsettes og lagene skilles. Den organiske fase ekstraheres med fortynnet saltsyreoppløsning. De sammenslåtte vannfaser vaskes med benzen og gjøres alkalisk med fortynnet natriumhydroksydopp-løsning samtidig som blandingen avkjøles i et isbad. Produktet ekstraheres 2 ganger med triklormetan. De sammenslåtte ekstrakter tørkes, filtreres og fordampes. Resten omdannes til etandioatsaltet i 2-propanol. Saltet frafiltreres og krystalliseres 2 ganger: first fra etanol og deretter fra metanol noe som gir 1 del N-(l-cyklopentyl-4-piperidinyl)-3-metyl-N-(2-pyrimidinyl)benzenacetamidetandioat med smeltepunkt 204,1°C. 2 parts sodium carbonate and 180 parts dimethylbenzene are stirred and boiled under reflux for 17 hours. A further 9 parts of 3-methylbenzeneacetyl chloride are added dropwise. After the addition has ended, stirring is continued for 67 hours at reflux temperature. The reaction mixture is cooled, water is added and the layers are separated. The organic phase is extracted with dilute hydrochloric acid solution. The combined aqueous phases are washed with benzene and made alkaline with dilute sodium hydroxide solution while the mixture is cooled in an ice bath. The product is extracted twice with trichloromethane. The combined extracts are dried, filtered and evaporated. The residue is converted to the ethanedioate salt in 2-propanol. The salt is filtered off and crystallized twice: first from ethanol and then from methanol, which gives 1 part of N-(1-cyclopentyl-4-piperidinyl)-3-methyl-N-(2-pyrimidinyl)benzeneacetamide ethanedioate with a melting point of 204.1°C .
Eksempel 15 Example 15
Ved å følge fremgangsmåten fra eks. 14 og ved å By following the procedure from e.g. 14 and by
bruke ekvivalente mengder av henholdsvis et passende N-aryl-4-piperidinamin og av et passende arylacetylklorid som utgansmat-eriale, ble de følgende forbindelser frembragt i baseform eller i form av syreaddisjonssalt etter behandling med en passende syre: using equivalent amounts of a suitable N-aryl-4-piperidinamine and of a suitable arylacetyl chloride respectively as starting materials, the following compounds were produced in base form or in acid addition salt form after treatment with a suitable acid:
Eksempel 16 Example 16
En blanding av 5 deler metyl-l-(l metyletyl)-4-(fenyl-amino)-4-piperidinkarboksylat, 24 deler 4-klorbenzenacetylklorid, 4 deler natriumkarbonat og 180 deler dimetylbenzen omrøres og kokes under tilbakeløp i 32 timer. Reaksjonsblandingen avkjøles, vaskes med en fortynnet natriumhydroksydoppløsning og ekstraheres med en fortynnet saltsyreoppløsning: der tilveiebringes 3 lag. Oljen og vannfasen slås sammen og gjøres alkalisk med en fortynnet natriumhydroksydoppløsning. Produktet ekstraheres med 4-metyl-2-pentanon. Ekstraktet vaskes med vann, tørkes, filtreres og fordampes. Resten omdannes til etandioatsaltet i 2-propanol. Saltet frafiltreres og krystalliseres fra en blanding av 2-propanol og 2,2<1->oksybispropan noe som gir 5 deler (48%) metyl-4-[N-(4-klorfenyl)acetyl-N-fenylamino]-l-(1-metyletyl)-4-piperidinkarboksylatetandioat med smeltepunkt 154,2°C. A mixture of 5 parts of methyl 1-(1 methylethyl)-4-(phenylamino)-4-piperidine carboxylate, 24 parts of 4-chlorobenzene acetyl chloride, 4 parts of sodium carbonate and 180 parts of dimethylbenzene is stirred and refluxed for 32 hours. The reaction mixture is cooled, washed with a dilute sodium hydroxide solution and extracted with a dilute hydrochloric acid solution: 3 layers are provided. The oil and water phase are combined and made alkaline with a dilute sodium hydroxide solution. The product is extracted with 4-methyl-2-pentanone. The extract is washed with water, dried, filtered and evaporated. The residue is converted to the ethanedioate salt in 2-propanol. The salt is filtered off and crystallized from a mixture of 2-propanol and 2,2<1->oxybispropane which gives 5 parts (48%) of methyl-4-[N-(4-chlorophenyl)acetyl-N-phenylamino]-l- (1-Methylethyl)-4-piperidine carboxylate ethanedioate with melting point 154.2°C.
Eksempel 17 Example 17
Ved å anvende fremgangsmåten fra eks. 16 og ved å bruke ekvivalente mengder av henholdsvis et passende 4-aryl-amino-4-piperidinkarboksylat og et passende arylacetylklorid som utgangsmateriale ble de følgende forbindelser tilveiebragt i form av fri base eller i form av et syreaddisjonssalt etter behandling med den passende syre: By using the procedure from e.g. 16 and using equivalent amounts of a suitable 4-aryl-amino-4-piperidine carboxylate and a suitable arylacetyl chloride respectively as starting material, the following compounds were provided in the form of a free base or in the form of an acid addition salt after treatment with the appropriate acid:
Eksempel 18 Example 18
Til en omrørt blanding av 4,4 deler 1-(1-metyletyl)-N-fenyl-4-piperidinamin, 5,3 deler natriumkarbonat og 180 deler benzen tilsettes dråpevis 5 deler benzenacetylklorid. Etterat tilsatsen er avsluttet, fortsettes omrøringen over natten ved tilbakeløpstemperatur. Reaksjonsblandingen avkjøles, vaskes med vann, natriumhydrogenkarbonatoppløsning og igjen med vann, tørkes, filtreres og fordampes. Resten omdannes til hydrokloridsaltet i 2,2'-oksybispropan og 2-propanol. Det dannede salt frafiltreres og krystalliseres fra en blanding av 2-propanol og 2,2<1->oksybispropan noe som gir 2,5 deler N-[1-(1-metyletyl)-4-piperidinyl]-N-fenylbenzenacetamidhydroklorid med smeltepunkt 184,4°C. To a stirred mixture of 4.4 parts of 1-(1-methylethyl)-N-phenyl-4-piperidinamine, 5.3 parts of sodium carbonate and 180 parts of benzene, 5 parts of benzene acetyl chloride are added dropwise. After the addition has ended, stirring is continued overnight at reflux temperature. The reaction mixture is cooled, washed with water, sodium bicarbonate solution and again with water, dried, filtered and evaporated. The residue is converted to the hydrochloride salt in 2,2'-oxybispropane and 2-propanol. The salt formed is filtered off and crystallized from a mixture of 2-propanol and 2,2<1->oxybispropane which gives 2.5 parts of N-[1-(1-methylethyl)-4-piperidinyl]-N-phenylbenzeneacetamide hydrochloride of m.p. 184.4°C.
Eksempel 19 Example 19
Ved å anvende fremgangsmåten fra eks. T5 og ved å bruke ekvivalente mengder av henholdsvis et passende stort N-aryl-4-piperidinamin og av et passende arylacetylklorid som utgangsmateriale, ble følgende forbindelser tilveiebragt i baseform eller i form av et syreaddisjonssalt etter behandling med den passende syre: By using the procedure from e.g. T5 and using equivalent amounts of a suitable large N-aryl-4-piperidinamine and of a suitable arylacetyl chloride respectively as starting material, the following compounds were provided in base form or in the form of an acid addition salt after treatment with the appropriate acid:
Eksempel 20 Example 20
En suspensjon av 1,25 deler natriumamid i A suspension of 1.25 parts sodium amide i
56 deler benzen omrøres under nitrogenatmosfære og varmes ved en temperatur på 40°C. Deretter tilsettes blandingen dråpevis en oppløsning av 6 deler N-(4-klorfenyl)-1-(1-metyletyl)-4-piperidinamin i 56 deler benzen. Etterat tilsatsen er avsluttet, omrører blandingen og kokes under tilbakeløp i 16 timer og 45 min. Blandingen avkjøles til 25°C og det tilsettess en blanding av 7,8 deler 3,4-diklorbenzenacetylklorid i 88 deler benzen. Etter omrøring og koking under tilbakeløp i ytterligere 2 timer, avkjøles reaksjonsblandingen og 80 deler vann tilsettes. Det hele surgjøres med fortynnet saltsyreoppløsning. Den vandige, sure fase gjøres alkalisk med natriumhydroksydoppløsning og den frie base ekstraheres med trikloretan. Ekstraktet tørkes, filtreres og fordampes. Resten oppløses i en blanding av 80 deler 1,1'-oksybisetan og 120 deler heksan. Oppløsningen avkjø-les over natten ved -10°C, frafiltreres noen urenheter og filtratet fordampes igjen. Resten oppløses i 120 deler 1,1'-oksybisetan, behandles med aktivt kull, filtreres og fordampes. 56 parts of benzene are stirred under a nitrogen atmosphere and heated at a temperature of 40°C. A solution of 6 parts of N-(4-chlorophenyl)-1-(1-methylethyl)-4-piperidineamine in 56 parts of benzene is then added dropwise to the mixture. After the addition has ended, the mixture is stirred and refluxed for 16 hours and 45 minutes. The mixture is cooled to 25°C and a mixture of 7.8 parts of 3,4-dichlorobenzeneacetyl chloride in 88 parts of benzene is added. After stirring and refluxing for a further 2 hours, the reaction mixture is cooled and 80 parts water is added. The whole is acidified with diluted hydrochloric acid solution. The aqueous, acidic phase is made alkaline with sodium hydroxide solution and the free base is extracted with trichloroethane. The extract is dried, filtered and evaporated. The residue is dissolved in a mixture of 80 parts of 1,1'-oxybisethane and 120 parts of hexane. The solution is cooled overnight at -10°C, some impurities are filtered off and the filtrate is evaporated again. The residue is dissolved in 120 parts of 1,1'-oxybisethane, treated with activated carbon, filtered and evaporated.
Den siste rest krystalliseres fra heksan ved -10°C noe som gir 2,2 deler 3,4-diklor-N-(4-klorfenyl)-N-[1-(1-metyletyl)-4-pip-eridinyl ] benzenacetamid med smeltepunkt 101,7°C. The last residue is crystallized from hexane at -10°C giving 2.2 parts of 3,4-dichloro-N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]benzeneacetamide with melting point 101.7°C.
Eksempel 21 Example 21
Ved å anvende fremgangsmåten fra eks. 20 og ved å bruke ekvivalente mengder av henholdsvis et passende N-aryl-4-piperidinamin og et passende arylacetylklorid som utgangsmateriale ble føglende forbindelser tilveiebragt i baseform eller i form av syreaddisjonssalt etter behandling med den passende syre: 4-brom-N-(4-klorfenyl)-N-[1-(1-metyletyl)-4-piperidinyl]-benzenacetamid; smp. 118,1°C; By using the procedure from e.g. 20 and using equivalent amounts of a suitable N-aryl-4-piperidinamine and a suitable arylacetyl chloride respectively as starting material, the following compounds were provided in base form or in acid addition salt form after treatment with the appropriate acid: 4-bromo-N-(4 -chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]-benzeneacetamide; m.p. 118.1°C;
4-klor-N-(2,6-dimetylfenyl)-N-[1-(1-metyletyl)-4-piperidinyl]-benzenacatmidhydroklorid; smp. 268,2°C; 4-chloro-N-(2,6-dimethylphenyl)-N-[1-(1-methylethyl)-4-piperidinyl]-benzeneacetamide hydrochloride; m.p. 268.2°C;
N-(4-klorfenyl)-4-(1-metyletyl)-N-[l-(1-metyletyl)-4-piperidinyl]-benzenacetamid; smp. 104,9°C. N-(4-chlorophenyl)-4-(1-methylethyl)-N-[1-(1-methylethyl)-4-piperidinyl]-benzeneacetamide; m.p. 104.9°C.
Eksempel 22 Example 22
5 deler 4-klor-N-(4-klorfenyl)-N-[1-(1-metyletyl)-4-piperidinyl]benzenacetamid oppløses i en blanding av 60 deler 1,1'-oksybisetan og 16 deler 2-propanon. Den resulterende opp-løsning surgjøres med et overskudd av 2-propanol som tidligere er blitt mettet med gassformet hydrogenklorid. Det utfelte salt frafiltreres og tørkes noe som gir 7,5 deler 4-klor-N-(4-klor-fenyl )-N-[1-(1-metyletyl)-4-piperidinyl]benzenacetamidhydro-klorid med smeltepunkt 266,6°C. 5 parts of 4-chloro-N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]benzeneacetamide are dissolved in a mixture of 60 parts of 1,1'-oxybisethane and 16 parts of 2-propanone. The resulting solution is acidified with an excess of 2-propanol which has previously been saturated with gaseous hydrogen chloride. The precipitated salt is filtered off and dried, which gives 7.5 parts of 4-chloro-N-(4-chloro-phenyl)-N-[1-(1-methylethyl)-4-piperidinyl]benzeneacetamide hydrochloride with a melting point of 266.6 °C.
Eksempel 23 Example 23
Fra 6 deler N-[1-(1-metyletyl)-4-piperidinyl]-N-fenyl-2-tiofenacetamid (E)-2-butendioat frigjøres den frie base på vanlig måte med fortynnet natriumhydroksydoppløsning. Produktet ekstraheres med triklormetan. Ekstraktet vaskes med vann, tørkes, filtreres og fordampes. Resten omdannes til etandioatsaltet i 2-propanol. Saltet frafiltreres og tørkes noe som gir 3,2 deler N-[1-(l-metyletyl-4-piperidinyl]-N-fenyl- From 6 parts of N-[1-(1-methylethyl)-4-piperidinyl]-N-phenyl-2-thiophenacetamide (E)-2-butenedioate, the free base is released in the usual way with dilute sodium hydroxide solution. The product is extracted with trichloromethane. The extract is washed with water, dried, filtered and evaporated. The residue is converted to the ethanedioate salt in 2-propanol. The salt is filtered off and dried, which gives 3.2 parts of N-[1-(1-methylethyl-4-piperidinyl]-N-phenyl-
2-tiofenacetamidetandioat med smeltepunkt 167,4°C. 2-thiophenacetamide ethanedioate with melting point 167.4°C.
Eksempel 24 Example 24
Fra en vandig oppløsning av 2,8 deler N-(2,6-dimety1-fenyl)-N-(l-propyl-4-piperidinyl)-2-tiofenacetamiddihydroklorid frigjøres den frie base ved alkalisering med natriumhydrogenkar-bonatoppløsning. Den frie base ekstraheres med 1,1'-oksybisetan. Ekstraktet tørkes og fordampes. Den oljeaktige rest opp-løses i 56 deler heksan og etter avkjøling til -10°C utfelles den frie base. Den frafiltreres og tørkes noe som gir 1,6 deler N-(2,6- dimetylfenyl)-N-(1-propyl-4-piperidinyl)-2-tiofenacetamid med smeltepunkt 6 2,5°C. From an aqueous solution of 2.8 parts of N-(2,6-dimethyl-phenyl)-N-(1-propyl-4-piperidinyl)-2-thiophenacetamide dihydrochloride, the free base is liberated by alkalization with sodium bicarbonate solution. The free base is extracted with 1,1'-oxybisethane. The extract is dried and evaporated. The oily residue is dissolved in 56 parts of hexane and after cooling to -10°C the free base is precipitated. It is filtered off and dried, which gives 1.6 parts of N-(2,6-dimethylphenyl)-N-(1-propyl-4-piperidinyl)-2-thiophenacetamide with melting point 6 2.5°C.
Eksempel 25 Example 25
Fra 3,9 deler N-(l-cyklopentyl-4-piperidinyl)-3-metyl-N-(3-pyridinyl)benzenacetamid (E)-2-butendioat, frigjøres den frie base på vanlig måte med fortynnet natriumhydroksydopp-løsning. Etter ekstraksjon med 2,2'-oksybispropan vaskes den sistnevnte med vann, tørkes, filtreres og fordampes. Resten omdannes til etandioatsaltet i etanol. Saltet frafiltreres og krystalliseres fra en blanding av etanol og 2,2'-oksybispropan noe som gir 3 deler N—(1-cyklopentvD-4-piperidinyl)-3-metyl-N-(3-pyridinyl)benzenacetamidetandioat med smeltepunkt 192,6°C. From 3.9 parts of N-(1-cyclopentyl-4-piperidinyl)-3-methyl-N-(3-pyridinyl)benzeneacetamide (E)-2-butenedioate, the free base is liberated in the usual way with dilute sodium hydroxide solution. After extraction with 2,2'-oxybispropane, the latter is washed with water, dried, filtered and evaporated. The residue is converted to the ethanedioate salt in ethanol. The salt is filtered off and crystallized from a mixture of ethanol and 2,2'-oxybispropane which gives 3 parts of N-(1-cyclopentylD-4-piperidinyl)-3-methyl-N-(3-pyridinyl)benzeneacetamide ethanedioate with a melting point of 192.6 °C.
Eksempel 26Example 26
En blanding av 50 deler 4-(£enylamino)-l-(f enylmetyl) - 4-piperidinkarboksamid i 600 deler konsentrert saltsyreoppløs-ning kokes under tilbakeløp i 16 timer. Etter avkjølingen konsentreres reaksjonsblandingen under redusert trykk til et volum på 400 deler hvoretter det dannes en utfelling. Den frafiltreres, vaskes med vann og 2-propanon og tørkes, noe som gir 43 deler 4-(fenylamino)-1-(fenylmetyl)-4-piperidinkarboksylsyre-dihydroklorid med smeltepunkt 261-26 3°C (dekomponering). A mixture of 50 parts of 4-(£enylamino)-1-(phenylmethyl)-4-piperidinecarboxamide in 600 parts of concentrated hydrochloric acid solution is refluxed for 16 hours. After cooling, the reaction mixture is concentrated under reduced pressure to a volume of 400 parts, after which a precipitate is formed. It is filtered off, washed with water and 2-propanone and dried, giving 43 parts of 4-(phenylamino)-1-(phenylmethyl)-4-piperidinecarboxylic acid dihydrochloride, mp 261-263°C (decomposition).
En blanding av 19 deler 4-(fenylamino)-1-(fenylmetyl)-4-piperidinkarboksylsyre-dihydroklorid, 14,4 deler svovelsyre og 64 deler etanol omrøres og kokes under tilbakeløp i 16 timer. Oppløsningsmidlet dekanteres. Resten oppløses i vann. Den vandige oppløsning gjøres alkalisk med ammoniumhydroksyd og ekstraheres med en blanding av metylbenzen og 2,2'-propan. De sammenslåtte organiske lag tørkes over magnesiumsulfat, filtreres og fordampes. Den oljeaktige rest oppløses i 200 deler 2,2<1->oksybispropan og gassformig hydrogenklorid tilføres oppløsningen. A mixture of 19 parts of 4-(phenylamino)-1-(phenylmethyl)-4-piperidinecarboxylic acid dihydrochloride, 14.4 parts of sulfuric acid and 64 parts of ethanol is stirred and refluxed for 16 hours. The solvent is decanted. The rest is dissolved in water. The aqueous solution is made alkaline with ammonium hydroxide and extracted with a mixture of methylbenzene and 2,2'-propane. The combined organic layers are dried over magnesium sulphate, filtered and evaporated. The oily residue is dissolved in 200 parts of 2,2<1->oxybispropane and gaseous hydrogen chloride is added to the solution.
Det utfelte hydroklorid frafiltreres, vaskes med 2-propanol, filtreres igjen og tørkes, noe som gir 11,5 deler etyl-4-(fenyl-amino) -1-(fenylmetyl)-4-piperidinkarboksylat-dihydroklorid med smeltepunkt 212-214,4°C. The precipitated hydrochloride is filtered off, washed with 2-propanol, filtered again and dried, which gives 11.5 parts of ethyl 4-(phenyl-amino)-1-(phenylmethyl)-4-piperidinecarboxylate dihydrochloride with melting point 212-214, 4°C.
Til en omrørt oppløsning som kokes under tilbakeløp To a stirred solution which is boiled under reflux
og som består av 101,4 deler etyl-4-(fenylamino)-1-(fenylmetyl)-4-piperidinkarboksylat i 640 deler tørr benzen tilsettes dråpevis en oppløsning av 172 deler natriumdihydro-bis(2-metoksy-etoksy)aluminat 70% i benzen i 160 deler tørr bensen. Etterat tilsatsen er avsluttet, fortsettes omrøringen i 2 timer og 30 min. ved 80°C. Reaksjonsblandingen avkjøles, helles over i isvann, gjøres alkalisk med natriumhydroksydoppløsning og produktet ekstraheres med benzen. Ekstraktet vaskes to ganger med vann, tørkes, filtreres og fordampes. Resten omdannes til hydrokloridsaltet i 2-propanol og etter avkjøling, frafiltreres produktet. Det kokes en gang til i acetonitril og saltet frafiltreres igjen etter avkjøling. Den frie base frigjøres på vanlig måte. Etter ekstraksjon med 1,1'-oksybisetan, vaskes den sistnevnte med vann, tørkes og fordampes noe som gir 56,6 deler 4-(fenylamino)-1-(fenylmetyl)-4-piperidinmetanol som en oljeaktig rest. and which consists of 101.4 parts of ethyl 4-(phenylamino)-1-(phenylmethyl)-4-piperidine carboxylate in 640 parts of dry benzene, a solution of 172 parts of sodium dihydro-bis(2-methoxy-ethoxy)aluminate 70% is added dropwise in benzene in 160 parts of dry benzene. After the addition has ended, stirring is continued for 2 hours and 30 minutes. at 80°C. The reaction mixture is cooled, poured into ice water, made alkaline with sodium hydroxide solution and the product is extracted with benzene. The extract is washed twice with water, dried, filtered and evaporated. The residue is converted to the hydrochloride salt in 2-propanol and, after cooling, the product is filtered off. It is boiled once more in acetonitrile and the salt is filtered off again after cooling. The free base is released in the usual way. After extraction with 1,1'-oxybisethane, the latter is washed with water, dried and evaporated to give 56.6 parts of 4-(phenylamino)-1-(phenylmethyl)-4-piperidinemethanol as an oily residue.
Til en oppløsning av 32 deler 4-(fenylamino)-1-(fenylmetyl) -4-piperidinmetanol i 90 deler benzen tilsettes 0,2 deler N,N,N-trietylbenzenmetanaminium-klorid og 150 deler natriumhyd-roksydoppløsning 60%. Etter heftig omrøring tilsettes dråpevis 10,9 deler dimetylsulfat ved en temperatur under 30°C. Etterat tilsatsen er avsluttet, fortsettes omrøringen ved værelsestemperatur først i 2 timer og 30 min og deretter etter tilsats av en annen porsjon av 2,6 deler dimetylsulfat, i 1 time og 30 min., Reaksjonsblandingen avkjøles i isvann og 200 deler vann tilsettes. Den organiske fase fraskilles og vannfasen ekstraheres med benzen. De sammenslåtte organiske faser vaskes med vann, tørkes, filtreres og fordampes. Resten renses ved kolonnekromatografi over silikagel under anvendelse av en blanding av triklormetan og 3% metanol mettet med ammoniakk som elueringsmiddel. De rene fraksjoner oppsamles og elueringsmidlet fordampes noe To a solution of 32 parts of 4-(phenylamino)-1-(phenylmethyl)-4-piperidinemethanol in 90 parts of benzene is added 0.2 parts of N,N,N-triethylbenzenemethanaminium chloride and 150 parts of sodium hydroxide solution 60%. After vigorous stirring, 10.9 parts of dimethylsulphate are added dropwise at a temperature below 30°C. After the addition has ended, the stirring is continued at room temperature first for 2 hours and 30 minutes and then, after the addition of another portion of 2.6 parts of dimethylsulphate, for 1 hour and 30 minutes, the reaction mixture is cooled in ice water and 200 parts of water are added. The organic phase is separated and the aqueous phase is extracted with benzene. The combined organic phases are washed with water, dried, filtered and evaporated. The residue is purified by column chromatography over silica gel using a mixture of trichloromethane and 3% methanol saturated with ammonia as eluent. The pure fractions are collected and the eluent is evaporated somewhat
som gir 24,8 deler 4-(metoksymetyl)-N-fenyl-1-(fenylmetyl)-4-piperidinamin som en rest. which gives 24.8 parts of 4-(methoxymethyl)-N-phenyl-1-(phenylmethyl)-4-piperidinamine as a residue.
En blanding av 10 deler 4-(metoksymetyl)-N-fenyl-1-(fenylmetyl)-4-piperidinamin og 200 deler eddiksyre hydrogeneres ved normalt trykk og værelsestemperatur med 2 deler palladium-på-kullkatalysator 10%. Etterat den beregnede mengde hydrogen er tatt opp, frafiltreres katalysatoren og filtratet fordampes. Den oljeaktige rest oppløses i vann, avkjøles og gjøres alkalisk med ammoniumhydroksyd. Produktet ekstraheres med triklormetan. Ekstraktet vaskes med vann, tørkes, filtreres og fordampes. Den oljeaktige rest renses ved kolonnekromatografi over silikagel under anvendelse av en blanding av triklormetan og metanol (90: 10 i volumsammensetning) mettet med gassformet ammoniakk som elueringsmiddel. De rene fraksjoner oppsamles og elueringsmidlet fordampes noe som gir 4,5 deler 4-(metoksymetyl)-N-fenyl-4-piperidinamin som en oljeaktig rest. A mixture of 10 parts of 4-(methoxymethyl)-N-phenyl-1-(phenylmethyl)-4-piperidinamine and 200 parts of acetic acid is hydrogenated at normal pressure and room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen has been taken up, the catalyst is filtered off and the filtrate is evaporated. The oily residue is dissolved in water, cooled and made alkaline with ammonium hydroxide. The product is extracted with trichloromethane. The extract is washed with water, dried, filtered and evaporated. The oily residue is purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (90:10 by volume) saturated with gaseous ammonia as eluent. The pure fractions are collected and the eluent evaporated to give 4.5 parts of 4-(methoxymethyl)-N-phenyl-4-piperidinamine as an oily residue.
En blanding av 10 deler 2-brompropan, 9 deler 4-(met-oksymetyl)- N-fenyl-4-piperidinamin, 4,9 deler N,N-dietyletan-amin og 7 2 deler N,N-dimetylacetamid omrøres og kokes under til-bakeløp i 10,25 timer. Etter avkjøling frafiltreres det dannede N-N-dietyletanaminhydrobromid, og filtratet fortynnes med vann. Produktet ekstraheres med metylbenzen. Ekstraktet vaskes godt med vann, tørkes, filtreres og fordampes. Resten renses ved kolonnekromatografi over silikagel under anvendelse av en blanding av triklormetan og metanol (90:10) som elueringsmiddel). A mixture of 10 parts of 2-bromopropane, 9 parts of 4-(methoxymethyl)-N-phenyl-4-piperidinamine, 4.9 parts of N,N-diethylethanamine and 72 parts of N,N-dimethylacetamide is stirred and boiled during the to-back race in 10.25 hours. After cooling, the formed N-N-diethylethanamine hydrobromide is filtered off, and the filtrate is diluted with water. The product is extracted with methylbenzene. The extract is washed well with water, dried, filtered and evaporated. The residue is purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (90:10) as eluent).
De rene fraksjoner oppsamles og elueringsmidlet fordampes noe som gir 5,7 deler (42,6%) 4-(metoksymetyl)-1-(1-metyletyl)-N-fenyl-4-piperidin som en oljeaktig rest. The pure fractions are collected and the eluent evaporated to give 5.7 parts (42.6%) of 4-(methoxymethyl)-1-(1-methylethyl)-N-phenyl-4-piperidine as an oily residue.
Til en omrørt blanding av 5,5 deler 4-(metoksymetyl)-1-(1-metyletyl)-N-fenyl-4-piperidinamin i 56 deler benzen tilsettes dråpevis en oppløsning av 13,8 deler benzenacetylklorid i 45 deler benzen ved 26-32°C. Etterat tilsatsen er avsluttet, fortsettes omrøringen først i 1 time ved 26-32°C og ytterligere i 3 timer og 40 min ved 38-55°C. Etter avkjøling frafiltreres det utfelte produkt og omdannes til hydrokloridsaltet i en blanding av 2-propanol og 2-propanon (i volumforholdet 5:1). Saltet frafiltreres og oppløses i absolutt etanol. Etter henstand i 72 timer ved værelsestemperatur, frafiltreres det utfelte produkt og vaskes med en liten mengde 2-propanon og tørkes, noe som gir 1,05 deler N-[4-(metoksymetyl)-1-(1-metyl-etyl) -4-piperidinyl]-N-fenylbenzenacetamidhydroklorid med smeltepunkt 2 4 9,1°C. To a stirred mixture of 5.5 parts of 4-(methoxymethyl)-1-(1-methylethyl)-N-phenyl-4-piperidinamine in 56 parts of benzene is added dropwise a solution of 13.8 parts of benzene acetyl chloride in 45 parts of benzene at 26 -32°C. After the addition has ended, the stirring is continued first for 1 hour at 26-32°C and for a further 3 hours and 40 minutes at 38-55°C. After cooling, the precipitated product is filtered off and converted to the hydrochloride salt in a mixture of 2-propanol and 2-propanone (in a volume ratio of 5:1). The salt is filtered off and dissolved in absolute ethanol. After standing for 72 hours at room temperature, the precipitated product is filtered off and washed with a small amount of 2-propanone and dried, yielding 1.05 parts of N-[4-(methoxymethyl)-1-(1-methyl-ethyl)- 4-piperidinyl]-N-phenylbenzeneacetamide hydrochloride with melting point 2 4 9.1°C.
E ksempel 27 Example 27
Til en omrørt blanding av 7,5 deler N-(4-klorfenyl)-1-(1-metyletyl)-4-piperidinamin og 80 deler 4-metyl-2-pentanon tilsettes dråpevis 8 deler [4-(2-klor-2-oksoetyl)fenyl]etyl-karbonat. Etterat tilsatsen er avsluttet, oppvarmes blandingen til tilbakeløpstemperaturen og omrøringen fortsettes i 1 time ved tilbakeløpstemperaturen. Etter avkjøling frafiltreres det utfelte produkt og omrøres i 30 min. i en blanding av alkalisk vann og triklormetan. Lagene skilles. Den organiske fase tørkes, filtreres og fordampes. Den oljeaktige rest renses ved kolonnekromatografi over silikagel under anvendelse av en blanding av triklormetan og metanol (i volumforholdet 90:10) som elueringsmiddel. De rene fraksjoner oppsamles og elueringsmidlet fordampes noe som gir 5,5 deler ^4-£2-{(4-klorfenyl)-[1-(1-metyletyl)-4-piperidinyl]amino}-2-oksoetyljfenyl^etylkarbonat som en oljeaktig rest. 8 parts of [4-(2-chloro- 2-oxoethyl)phenyl]ethyl carbonate. After the addition is complete, the mixture is heated to the reflux temperature and stirring is continued for 1 hour at the reflux temperature. After cooling, the precipitated product is filtered off and stirred for 30 min. in a mixture of alkaline water and trichloromethane. The teams are separated. The organic phase is dried, filtered and evaporated. The oily residue is purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (in the volume ratio 90:10) as eluent. The pure fractions are collected and the eluent evaporated to give 5.5 parts of ^4-£2-{(4-chlorophenyl)-[1-(1-methylethyl)-4-piperidinyl]amino}-2-oxoethyljphenyl^ethylcarbonate as a oily residue.
En blanding av 5,5 deler av ^4-j^ 2-{ (4-klorf enyl) [ 1-(1-metyletyl)-4-piperidinyl]amino}-2-oksoetyl fenyl^etylkarbo-nat og 50 deler natriumhydroksydoppløsning 10% omrøres i 90 min. ved 45°C. Reaksjonsblandingen avkjøles til værelsestemperatur og surgjøres med eddiksyre til pH 5,5-6. Produktet ekstraheres med trikloretan. Ekstraktet tørkes, filtreres og fordampes. Den oljeaktige rest renses ved kolonnekromatografi over silikagel under anvendelse av en blanding av triklormetan og metanol (i volumforholdet 80:20) som elueringsmiddel. De rene fraksjoner oppsamles og elueringsmidlet fordampes. Den oljeaktige rest ble omdannet til hydrokloridsaltet i 4-metyl-2-pentanon. Saltet frafiltreres og tørkes i vakuum i 12 timer ved 60°C noe som gir 1,9 deler N-(4-klorfenyl)-4-hydroksy-N-[1-(1-metyletyl)-4-piperidinyl]benzenacetamidmonohydroklorid med smeltepunkt 24 2,9°C. A mixture of 5.5 parts of ^4-j^ 2-{ (4-chlorophenyl) [ 1-(1-methylethyl)-4-piperidinyl]amino}-2-oxoethyl phenyl^ethyl carbonate and 50 parts of sodium hydroxide solution 10% is stirred for 90 min. at 45°C. The reaction mixture is cooled to room temperature and acidified with acetic acid to pH 5.5-6. The product is extracted with trichloroethane. The extract is dried, filtered and evaporated. The oily residue is purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (in the volume ratio 80:20) as eluent. The pure fractions are collected and the eluent is evaporated. The oily residue was converted to the hydrochloride salt of 4-methyl-2-pentanone. The salt is filtered off and dried in vacuo for 12 hours at 60°C, which gives 1.9 parts of N-(4-chlorophenyl)-4-hydroxy-N-[1-(1-methylethyl)-4-piperidinyl]benzeneacetamide monohydrochloride with m.p. 24 2.9°C.
Eksempel 2 8 Example 2 8
En blanding av 8 deler 2-propanon og 9,9 deler N-(4-klorfenyl)-N-(4-piperidinyl)-benzenacetamid-hydroklorid i 16 9 deler metanol hydreres ved normaltrykk og romtempera-tur med 2 deler 10% palladium-på-trekull-katalysator. A mixture of 8 parts 2-propanone and 9.9 parts N-(4-chlorophenyl)-N-(4-piperidinyl)-benzeneacetamide hydrochloride in 16 9 parts methanol is hydrated at normal pressure and room temperature with 2 parts 10% palladium -on-charcoal catalyst.
Etter at den beregnede mengde hydrogen er tatt opp, filtreres katalysatoren av og filtratet dampes inn. Resten tas opp i en blanding av 2-propanon og 1,1<1->oksobispropan og felles ut som hydrokloridsaltet. Produktet filtreres av og tørkes og man oppnår 6,3 deler N-(4-klorfenyl)-N-[1-fi-me tyle tyl )-4-piperidinyl]-benzenacetamid-hydroklorid med smeltepunkt 262,3°C. After the calculated amount of hydrogen has been taken up, the catalyst is filtered off and the filtrate is evaporated. The residue is taken up in a mixture of 2-propanone and 1,1<1->oxobispropane and precipitated as the hydrochloride salt. The product is filtered off and dried and 6.3 parts of N-(4-chlorophenyl)-N-[1-methylethyl)-4-piperidinyl]-benzeneacetamide hydrochloride with a melting point of 262.3°C are obtained.
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61513175A | 1975-09-23 | 1975-09-23 | |
US71375676A | 1976-08-12 | 1976-08-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO763054L NO763054L (en) | 1977-03-24 |
NO147672B true NO147672B (en) | 1983-02-14 |
NO147672C NO147672C (en) | 1983-05-25 |
Family
ID=27087421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO763054A NO147672C (en) | 1975-09-23 | 1976-09-06 | ANALOGUE PROCEDURE FOR PREPARING N-ARYL-N- (1-L1-4-PIPERIDINYL) -ARYLACETAMIDES |
Country Status (29)
Country | Link |
---|---|
JP (1) | JPS6016417B2 (en) |
AT (1) | AT363935B (en) |
AU (1) | AU510029B2 (en) |
BG (1) | BG27543A3 (en) |
CA (1) | CA1068271A (en) |
CH (1) | CH628623A5 (en) |
CS (1) | CS222663B2 (en) |
DE (1) | DE2642856A1 (en) |
DK (1) | DK150478C (en) |
ES (1) | ES451768A1 (en) |
FI (1) | FI61482C (en) |
FR (1) | FR2325377A1 (en) |
GB (1) | GB1539473A (en) |
GR (1) | GR58469B (en) |
HU (1) | HU172964B (en) |
IE (1) | IE43802B1 (en) |
IL (1) | IL50522A (en) |
IT (1) | IT1073893B (en) |
LU (1) | LU75837A1 (en) |
NL (1) | NL187267C (en) |
NO (1) | NO147672C (en) |
NZ (1) | NZ181972A (en) |
PH (1) | PH12497A (en) |
PL (2) | PL192578A1 (en) |
PT (1) | PT65631B (en) |
RO (1) | RO70079A (en) |
SE (1) | SE427839B (en) |
SU (1) | SU747424A3 (en) |
YU (1) | YU39973B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA765684B (en) * | 1975-09-23 | 1978-04-26 | Janssen Pharmaceutica Nv | Novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
JPS62260786A (en) * | 1986-05-08 | 1987-11-13 | 株式会社ヘキトク | Line system for manufacturing smoked roof tile |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Fast Dissociting Dopamine 2 Receptor Antagonists |
JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Fast Dissociating Dopamine 2 Receptor Antagonists |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Fast -Dissociating Dopamine 2 Receptor Antagonists |
WO2008128996A1 (en) | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
KR20100016498A (en) * | 2007-04-23 | 2010-02-12 | 얀센 파마슈티카 엔.브이. | Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists |
JP5431305B2 (en) | 2007-04-23 | 2014-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4-Alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists |
CA2729313C (en) | 2008-07-03 | 2016-08-30 | Janssen Pharmaceutica Nv | Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists |
EP2307374B1 (en) | 2008-07-31 | 2017-01-25 | Janssen Pharmaceutica NV | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
CN118496638B (en) * | 2024-07-22 | 2024-11-22 | 海安浩驰科技有限公司 | Anti-ultraviolet window film and preparation method thereof |
-
1976
- 1976-09-06 NO NO763054A patent/NO147672C/en unknown
- 1976-09-08 NZ NZ181972A patent/NZ181972A/en unknown
- 1976-09-16 FR FR7627870A patent/FR2325377A1/en active Granted
- 1976-09-17 AU AU17878/76A patent/AU510029B2/en not_active Expired
- 1976-09-20 RO RO7687590A patent/RO70079A/en unknown
- 1976-09-20 CA CA261,551A patent/CA1068271A/en not_active Expired
- 1976-09-20 LU LU75837A patent/LU75837A1/xx unknown
- 1976-09-21 CH CH1194876A patent/CH628623A5/en not_active IP Right Cessation
- 1976-09-21 IT IT51370/76A patent/IT1073893B/en active
- 1976-09-21 GB GB39099/76A patent/GB1539473A/en not_active Expired
- 1976-09-21 JP JP51112527A patent/JPS6016417B2/en not_active Expired
- 1976-09-21 IL IL50522A patent/IL50522A/en unknown
- 1976-09-21 GR GR51742A patent/GR58469B/en unknown
- 1976-09-22 PT PT65631A patent/PT65631B/en unknown
- 1976-09-22 PL PL19257876A patent/PL192578A1/en not_active IP Right Cessation
- 1976-09-22 FI FI762698A patent/FI61482C/en not_active IP Right Cessation
- 1976-09-22 HU HU76JA00000767A patent/HU172964B/en not_active IP Right Cessation
- 1976-09-22 PL PL1976216213A patent/PL117323B1/en unknown
- 1976-09-22 DK DK427876A patent/DK150478C/en active
- 1976-09-22 IE IE2095/76A patent/IE43802B1/en unknown
- 1976-09-22 PH PH18928A patent/PH12497A/en unknown
- 1976-09-22 CS CS766139A patent/CS222663B2/en unknown
- 1976-09-22 ES ES451768A patent/ES451768A1/en not_active Expired
- 1976-09-22 YU YU2336/76A patent/YU39973B/en unknown
- 1976-09-22 AT AT0702976A patent/AT363935B/en not_active IP Right Cessation
- 1976-09-22 SE SE7610501A patent/SE427839B/en not_active IP Right Cessation
- 1976-09-22 NL NLAANVRAGE7610513,A patent/NL187267C/en not_active IP Right Cessation
- 1976-09-23 BG BG034265A patent/BG27543A3/en unknown
- 1976-09-23 SU SU762405548A patent/SU747424A3/en active
- 1976-09-23 DE DE19762642856 patent/DE2642856A1/en active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4126689A (en) | N-aryl-n-(1-alkyl-4-piperidinyl)-arylacetamides | |
JP4758609B2 (en) | γ-secretase inhibitor | |
KR100244063B1 (en) | Novel N-alkylene piperidino compounds and their enantiomers, methods for their preparation and pharmaceutical compositions containing them | |
FI61481C (en) | FRAMEWORK FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC PIPERIDINDERIVAT | |
EP1263729B1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
CA2455863C (en) | Tetrahydroquinoline derivatives as gamma secretase inhibitors | |
EP1758580A2 (en) | N-substituted piperidines and their use as pharmaceuticals | |
CA2454613A1 (en) | Substituted anilinic piperidines as mch selective antagonists | |
US4369184A (en) | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives | |
WO2005103033A1 (en) | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | |
AU2006309050B2 (en) | Piperidine glycine transporter inhibitors | |
NO147672B (en) | ANALOGUE PROCEDURE FOR PREPARING N-ARYL-N- (1-L1-4-PIPERIDINYL) -ARYLACETAMIDES | |
US5830906A (en) | Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | |
US3041344A (en) | 1-(aroylalkyl)-4-piperidinecarboxamides | |
US20040229864A1 (en) | Sulfone derivatives as 5-HT7 receptor ligands | |
US4197304A (en) | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides | |
US4196210A (en) | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides | |
US4151286A (en) | N-aryl-N-(1-L-4-piperidinyl)-arylacetamides | |
KR100652450B1 (en) | N-ureido-piperidine as antagonist VIII for the CCR-3 receptor | |
US4197303A (en) | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides | |
US4208418A (en) | N-Aryl-N-(1-alkyl-4-piperidinyl)arylacetamides | |
KR810000430B1 (en) | Process for preparing n-aryl-n-(1-l-4-piperidinyl)-arylacetamides | |
WO2007090826A1 (en) | Piperidine derivatives as cxcr3 receptor antagonists | |
US4198411A (en) | N-aryl-N-(1-L-4-piperidinyl)-arylaceytamides | |
DK153474B (en) | Analogy method for preparation of N-aryl-N-(4-piperidyl)- arylacetamide derivatives |